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Summary 
 
La tubercolosi (TB) è una malattia di origine infettiva causata dal bacillo 
Mycobacterium tuberculosis (MTB), chiamato anche Bacillo di Koch. Essa figura al 
secondo posto nelle cause di morte per malattie infettive in tutto il mondo dopo lo 
Human Immunodeficiency Virus (HIV). Nel 1993, la TB è stata classificata come 
emergenza mondiale dalla World Health Organisation (WHO) che ha stimato circa 9 
milioni di nuovi casi nel 2011 e  1.4 milioni di decessi dovuti alla TB in 84 Paesi. La  
stessa WHO considera l'Italia uno dei paesi occidentali in cui si sarebbe verificato, tra 
il 1988 ed il 1990, il maggior incremento del numero di casi di TB. Nonostante la 
disponibilità di trattamenti efficaci e poco costosi, la tubercolosi risulta più diffusa 
nella popolazione povera che tra quella ricca, sia nelle regioni industrializzate che 
nelle regioni in via di sviluppo. Le regioni nelle quali si riscontra il 60% dei casi totali 
di TB sono: Pakistan, sud dell’Africa, China e India. Il più alto tasso di incidenza della 
tubercolosi si riscontra nell’Africa Sub-Sahariana, soprattutto associata all’infezione 
da (HIV). Oltre all’infezione da HIV, l’incremento nel tasso di incidenza della 
tubercolosi è provocato dalla comparsa di ceppi resistenti alla maggior parte dei 
farmaci anti-TB. Altri fattori che incidono sulla diffusione della TB sono: l’aumento 
della popolazione; la difficoltà a rilevare i casi tra le masse povere; il ridotto tasso di 
cure in paesi in via di sviluppo; la trasmissione dell’infezione in ospedali e prigioni 
sovraffollati e l’immigrazione di individui da paesi dove la TB è endemica (WHO 
2012). 
La principale fonte di contagio è rappresentata dalle persone affette da TB, anche se 
soltanto il 10% degli individui mostra i segni di tubercolosi attiva entro i 18 mesi 
dall’avvenuta infezione. Nei restanti casi, la risposta immunitaria conseguente 
all’infezione riesce ad arrestare la crescita del MTB. Ciò nonostante, il patogeno è 
completamente eradicato soltanto nel 10% dei casi mentre, nel restante 90%, il MTB 
riesce ad eludere i meccanismi antibatterici delle cellule del sistema immunitario 
restando in uno stato non-replicativo (dormiente o latente). Questo processo è 
chiamato Latent Tuberculosis Infection (LTI) e colpisce circa due miliardi di persone 
al mondo (Koul, Herget et al. 2004).  
 
Mycobacterium tuberculosis 
 
Il Mycobacterium tuberculosis è un membro della specie Mycobacterium tuberculosis 
complex (MTBC). Ad esso appartengono altre 6 specie correlate geneticamente: M. 
bovis, M. africanum, M. microti, M. pinnipedii, M. caprae e M. capretti. Tutte possono 
provocare tubercolosi, ma hanno un diverso host range (Cole, Brosch et al. 1998).  
 Il M. tuberculosis ha una struttura unica che lo rende diverso da tutti gli altri batteri. 
Partendo dall’interno verso l’esterno troviamo la membrana cellulare rivestita da 
diversi strati di peptidoglicano (PG), arabinogalattani (AG), lipomannani (LM), 
mannose-lipoarabinomannani (ManLAM) e acidi micolici (MA) legati covalentemente 
tra di loro a formare una struttura molto complessa. Il peptidoglicano costituisce lo 
scheletro di questa struttura. Esso è costituito da lunghe catene di N-
acetilglucosammina (NAG) legate a catene di acido muramico (NAM) attraverso dei 
residui di L-alanyl-D-iso-glutaminyl-meso-diaminopimelic acid (DAP) (Velayati, Farnia 
et al. 2012). I polisaccaridi a lunga catena (LM, AG e LAM) formano un ponte tra il 
peptidoglicano e gli acidi micolici che sono acidi grassi a lunga catena che 
rappresentano i componenti principali della parete del micobatterio.  
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Riconoscimento del Mycobacterium tuberculosis 
 
I Pathogen-associated molecular patterns (PAMP) del MTB vengono riconosciuti da 
specifici Pathogen recognition receptors (PRRs) posti sulla superficie delle cellule del 
sistema immunitario dell’ospite. Questi recettori, tra cui i Toll-like receptors (TLRs) 
sono essenziali per coordinare la risposte immunitaria innata dell’ospite (Jo 2008). 
L’interazione tra i PAMPs del MTB ed i TLRs innesca una cascata di trasduzione del 
segnale che culmina in una risposta pro-infiammatoria da parte delle sistema 
immunitario dell’ospite (Harding and Boom 2010). Tuttavia, il micobatterio ha 
sviluppato efficaci strategie atte a modulare o addirittura inibire tale risposta. I più 
importanti ligandi posti sulla superficie del micobatterio i quali interagiscono con i 
TLRs sono: 19 kDa lipoprotein, il lipomannano (LM) ed il mannose-
lipoarabinomannano (Jo, Yang et al. 2007). L’interazione di questi ligandi con i TLRs 
porta all’attivazione del nuclear trascription factor B (NF-kB) e la conseguente 
produzione di citochine pro-infiammatorie come tumor necrosis factor-alpha (TNF-α), 
interferon-gamma (IFN-γ) e anche dell’ossido nitrico attraverso via myeloid 
differentiation primary response protein 88 (MyD88)-dipendenti che indipendenti 
(Yamamoto, Sato et al. 2003, Jo 2008). Uno studio ha mostrato che, almeno nel 
topo, il contatto prolungato con la 19 kDa del MTB da parte dei macrofagi alveolari 
attenua la processazione dell’antigene che a sua volta attenua l’espressione del 
major histocompatibility complex (MHC)-II  smorzando così l’attivazione delle T cells 
(Fulton, Reba et al. 2004). In questo modo, una sottopopolazione di macrofagi 
infettati con la funzione dell’APC modulata, costituisce una nicchia invisibile al 
sistema immunitario dove il batterio può sopravvivere e resistere.  
 
Scopo della tesi 
 
Schurr (Schurr 2007) si è chiesto se la tubercolosi fosse una malattia infettiva o 
ereditaria. L’autore sapeva molto bene che la tubercolosi può essere contratta solo in 
presenza del patogeno. Con la sua domanda (posta come titolo all’articolo), Schurr 
ha inteso mettere in evidenza il ruolo essenziale della componente ereditaria ai fini 
della resistenza alla tubercolosi. Indi per cui la ricerca si è incentrata 
sull’associazione (punto I) e interazione (punto II) tra i geni MyD88 e TIRAP e la 
tubercolosi. Entrambi i geni funzionano come trasmettitori del segnale dai recettori 
esterni alla cellula fino all’interno del nucleo dove avviene la trascrizione di geni 
capaci di innescare la risposta immune, innata e adattativa. Inoltre, la loro posizione 
su cromosomi distinti (indipendenza) e la loro comune funzione (trasmissione del 
segnale) rende plausibile l’ipotesi che i geni interagissero. Anche quest’anticipazione 
si è dimostrata valida, offrendo un esempio di epistasi (interazione tra geni non alleli). 
Inoltre, la letteratura scientifica inerente al coinvolgimento di MyD88 e TIRAP nella 
tubercolosi presenta notevoli discrepanze, soprattutto nel delicato campo degli studi 
di associazione.  
Topi “knockout” per MyD88 mostrano una produzione di TNF-α, IL-12 e NO molto 
ridotta in risposta all’infezione dell’MTB e muoiono in 4 settimane (Fremond, 
Yeremeev et al. 2004). Topi “knockout” per TIRAP, invece, riescono a controllare 
efficacemente l’infezione  da MTB (Fremond, Togbe et al. 2007). Il Single-nucleotide 
polymorphism (SNP) C558T di TIRAP è associato con la suscettibilità alla tubercolosi 
meningea (Hawn, Dunstan et al. 2006, Caws, Thwaites et al. 2008), e quello S180L 
conferisce protezione contro la malaria e la tubercolosi (Khor, Chapman et al. 2007). 
Studi successivi non hanno confermato il ruolo protettivo di S180L (Nejentsev, Thye 
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et al. 2008, Miao, Li et al. 2011), TIRAP (rs352165 and rs352167) e MyD88 
(rs4988457 and rs6767684) contro la tubercolosi (Khor, Chapman et al. 2007, 
Nejentsev, Thye et al. 2008). Alla luce di queste discrepanze  emerse, perfino 
all’interno dello studio dello stesso SNP (rs81777374) in differenti etnie, si è deciso di 
investigare il ruolo di questi SNPs nei malati di tubercolosi polmonare nella 
popolazione italiana. In aggiunta, il M. tuberculosis ha l’abilità di passare dalla forma 
attiva a quella dormiente. Pertanto i geni MyD88 e TIRAP potrebbero influenzare 
diversamente le due forme d’infezione. In questo caso, l’eterogeneità dei pazienti 
(con infezione attiva e con infezione latente) può ridurre notevolmente il potere 
discriminante del test statistico (caso-controllo). Per investigare meglio questo punto 
dello studio, si è pensato di spostare la ricerca su di un altro modello: i bovini. Da 
questi animali è stato possibile ottenere biopsie polmonari al momento della 
macellazione. L’indagine ha chiarito che – come ipotizzato – il genotipo può 
influenzare l’infezione, in termini di interazione tra i geni e la il tipo di risposta attuato. 
 
Results 
Study design 
 
Per saggiare la riproducibilità dei risultati, è stato scelto uno studio a due fasi. Nella 
prima fase dello studio (hypotesis-generating) sono stati reclutati 100 casi e 100 
controlli e genotipizzati per il sito polimorfico TIRAP rs8177374 e MyD88 rs6853. 
Entrambi i siti sono stati scelti perché sono stati gli unici tra i 5 saggiati per gene a 
mostrare una frequenza allelica >0.05. Inoltre entrambi i siti hanno mostrato 
associazione statisticamente significativa con la malattia (P-value <0.05). Sulla base 
dei risultati dello studio preliminare (MyD88: OR 0.40 e TIRAP: 0.48), è stato 
calcolato che - per assicurare allo studio una capacità discriminante del 96% con un 
livello di significatività dello 0.01- fosse necessario estendere lo studio ad un 
campione di 185 casi e 185 controlli (nel caso di MyD88) e 313 casi e 313 controlli 
(nel caso di TIRAP). Nella seconda parte dello studio sono stati coinvolti 400 casi e 
400 controlli (indipendenti dai casi e dai controlli utilizzati nella fase preliminare dello 
studio). Per rendere la classe dei casi più omogenea possibile, sono stati reclutati 
solo pazienti con TB polmonare attiva confermata attraverso l’esame ai raggi X, il 
test batteriologico e la PCR. Tutti i casi sono stati trattati presso l’ospedale Monaldi 
(Napoli), il centro di referenza per la tubercolosi del Sud Italia. I controlli sono stati 
scelti tra mogli, mariti e conoscenti dei pazienti senza evidenze cliniche di tubercolosi 
(negativi al test con l’interferone gamma). In tal modo i controlli non sono correlati 
geneticamente ai casi e non risultano infettati, nonostante esposti al Mycobacterium 
tuberculosis (>2 anni). I criteri utilizzati per classificare casi e controlli sono stati gli 
stessi in entrambe le fasi dello studio. I casi ed i controlli sono stati collezionati 
durante più di 5 anni di collaborazione tra l’Ospedale ed il laboratorio della Prof.ssa 
Capparelli Rosanna. In questo tempo sei controlli sono diventati positivi al test con 
l’interferone e quindi sono stati esclusi dallo studio. I casi consistevano in 258 maschi 
e 142 femmine (media età 50±19 anni); i controlli in 222 maschi e 178 femmine 
(media età 49±17 anni). Lo studio è stato approvato dal comitato etico dell’Ospedale 
Monaldi. Il consenso informato è stato ottenuto da tutti i pazienti che hanno 
partecipato alla ricerca.  
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Eterozigosi è associata con la protezione contro la tubercolosi polmonare. 
 
Le frequenze genotipiche dei markers rs6853 e rs8177374 sono in equilibrio di 
Hardy-Weinberg tra i controlli, ma non tra i casi. Ad entrambi i loci, l’eterozigosi (AG 
per MyD88 o CT per TIRAP) è associata con la resistenza alla tubercolosi 
polmonare. L’età rappresenta un fattore di rischio per la tubercolosi polmonare. Per 
conoscere come il rischio legato all’età varia attraverso le stratificazioni, i dati sono 
stati analizzati utilizzando il modello della regressione logistica. L’analisi è stata 
ristretta ai gruppi con un numero ≥ di 45 individui. A parte la categoria 31-40 vs 21-30 
anni (apparentemente protetta, OR 0.31), il modello ha mostrato che il rischio di 
sviluppare la malattia aumenta con l’età. Chiaramente, l’età e le possibili variabili 
associate all’età - come il fumo, il diabete e la prolungata esposizione al patogeno - 
possono neutralizzare la resistenza genetica. Il modello di regressione logistica è 
stato anche usato per dissezionare il contributo di ogni singolo genotipo e la loro 
interazione. Particolarmente evidente è l’interazione tra i genotipi AG e CT (OR 0.09) 
e l’interazione in direzione opposta tra i genotipi GG e TT, AA e CC, AA e CT (OR 
5.78, 5.78 e 7.46, rispettivamente).  
 
L’eterozigosi controlla l’infiammazione 
 
Per investigare sul meccanismo di come l’ospite può controllare l’infezione secondo 
l’assetto genotipico, i linfociti di donatori sani (controlli) (nove gruppi genotipici; 5 
campioni/gruppo) sono stati stimolati con il ceppo Mycobacterium tuberculosis 
H37Rv inattivato al calore e poi sono stati misurati i livelli di TNF-α, IFN-ɣ e NO (nitric 
oxide) rilasciati nel mezzo attraverso un’ELISA test. Nel contesto del genotipo AA, i 
soggetti CT mostrano livelli intermedi di TNF-α, IFN-ɣ e NO rispetto ai soggetti CC e 
TT. Nel contesto genotipico AG, i dati mostrano la stessa tendenza, sebbene alcune 
differenze non siano significative. Inoltre, sono stati osservati bassi livelli di citochine 
in soggetti GG, come se l’allele “A” favorisse la produzione di citochine e l’allele “G” 
la attenuasse. Questi dati indicano che gli eterozigoti sono associati con un livello 
intermedio di citochine and NO. Questi risultati suggeriscono che i due loci 
cooperano fortemente a controllare la malattia. Questa evidenza è fortemente 
supportata dall’evidenza che TIRAP e MyD88 formano eterodimeri. 
 
Analisi bioinformatica  
 
Il sito rs6853 risiede nella regione 3’ UTR del gene MyD88. Comparando le 
sequenze genomiche di diverse specie emerge che entrambi gli alleli A e G sono 
conservati in molte specie, suggerendo che essi sono mantenuti o almeno tollerati, 
dalla selezione naturale. Attraverso l’analisi con 4 ENCODE tracks è emerso che la 
regione 3’ UTR del sito polimorfico potrebbe influenzare l’interazione tra l’mRNA ed 
fattori proteici. Il sito rs8177374, che risiede sull’esone 5 del gene TIRAP, ha 
permesso di valutare se il cambiamento di una serina con una leucina in posizione 
180 potesse influenzare la struttura della proteina. Entrambi gli amminoacidi sono 
rappresentati in posizione 180 dei geni TIRAP di 22 specie di mammiferi. E’ stato 
possibile predire che entrambi sono compatibili con l’attività della proteina. Questi 
risultati suggeriscono che le isoforme A e B sono originate dalla stessa molecola di 
mRNA che ha subito splicing alternativo conferendo una ulteriore plausibilità 
biologica al polimorfismo.  
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Discussione e conclusioni 
 
Molto poco è conosciuto del “crosstalk” tra geni implicati nella resistenza ad un 
patogeno. In questo lavoro è stato investigato come i geni MyD88 e TIRAP si 
influenzano a vicenda. L’ipotesi che i due geni potrebbero interagire sembra 
plausibile in quanto entrambe le proteine MyD88 e TIRAP sono coinvolte nel 
“signaling” cellulare a valle dei TLRs. Sempre in questo studio è stato dimostrato che 
i due geni cooperano o si antagonizzano tra di loro sulla base della loro 
combinazione allelica. L’eterozigosi ad entrambi i loci fornisce una protezione più 
forte (P= 1.3x10-12, age-corrected) rispetto all’eterozigosi ad un solo locus (MyD88 
P= 7.8x10-8; TIRAP P= 2x10-6). Allo stesso tempo, negli individui AG/TT 
(MyD88/TIRAP) il genotipo TT neutralizza la protezione apportata dal genotipo AG. 
Questi dati, seppur in maniera limitata, mostrano come due o più geni indipendenti 
possono concorrere alla formazione e regolazione dello stesso fenotipo. Gli individui 
eterozigoti ai loci MyD88 o TIRAP mostrano livelli intermedi di TNF-α, IFN-ɣ e NO 
rispetto alle altre classi genotipiche (Figure 1). TNF-α, IFN-ɣ e NO giocano un ruolo 
fondamentale contro Mycobacterium tuberculosis (Casanova and Abel 2002, 
Scanga, Bafica et al. 2004, Velez, Hulme et al. 2009). NO esercita una forte attività 
anti-micobatterica ed insieme a TNF-α, favorisce la formazione dei granulomi (Miller 
and Ernst 2009). IFN-ɣ induce la produzione di NO, l’espressione delle molecole 
MHC II e la presentazione dell’antigene (Fortune, Solache et al. 2004, Scanga, 
Bafica et al. 2004). Tuttavia, vi è anche l’evidenza che la sovra-espressione di queste 
molecole favorisce la tubercolosi. Molti dei sintomi sono proprio causati dalla risposta 
immune dell’ospite, piuttosto che dal Mycobacterium tuberculosis (Glickman and 
Jacobs 2001). Infatti, la riattivazione della TB si è osservata dopo il trattamento 
terapeutico con TNF-α (Mankia, Peters et al. 2011) o in pazienti affetti da HIV dopo 
trattamento antiretrovirale (French and Price 2001). Anche l’ipo-espressione di TNF-
α, IFN-ɣ e NO favorisce la TB, quindi il vantaggio biologico di averne un livello 
intermedio di espressione diventa chiaro. Questo vantaggio risulta molto più marcato 
nei doppi eterozigoti che mostrano come il crosstalk tra i geni si estenda dal livello 
epidemiologico a quello molecolare. Il vantaggio espresso dagli eterozigoti 
suggerisce che le frequenze alleliche ai siti polimorfici di rs6853 e rs8177374 sono 
mantenuti dal bilanciamento del polimorfismo, dove l’omozigosi è associato con la 
tubercolosi polmonare e l’eterozigosi alla resistenza. In accordo con questa ipotesi vi 
è il fatto che entrambi i siti polimorfici sono conservati attraverso la speciazione. 
Inoltre il fatto che la combinazione allelica influisce sui livelli di TNF-α, IFN-ɣ e NO 
suggerisce che l’associazione sia tra MyD88 e TIRAP piuttosto che tra geni 
strettamente correlati a loro. In conclusione, l’associazione di rs8177374 con la TB 
polmonare probabilmente sarà confermata anche in studi futuri, mentre rs6853 risulta 
associato in questo studio, ma non in due lavori precedenti (Miao, Li et al. 2011, 
Sanchez, Lefebvre et al. 2012), quindi al momento resta uno studio esplorativo 
hypothesis-testing study. 
 
Commento 
 
Purtroppo gli studi di associazione mancano di riproducibilità (Ioannidis, Ntzani et al. 
2001). Durante la prima fase dello studio siamo incappati in ostacoli più o meno 
appianabili. Per ridurre al minimo tutte le fonti di errore è stato fatto in modo che tutto 
lo studio fosse costruito intorno a precisi punti: replicazione dei risultati in maniera 
indipendente (studio a 2 fasi); bassi P-value (10-6-10-8); selezione di casi omogenei 
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(lo studio ha arruolato pazienti con tubercolosi polmonare clinicamente diagnosticata 
e confermata con X-ray al torace, PCR e positività al test batteriologico); uso di 
appropriati controlli (individui senza segni evidenti della malattia, ma esposti al 
patogeno e geneticamente non correlati ai casi). Inoltre, l’evidenza che 
l’associazione è mantenuta in 3 differenti etnie rendono improbabile che 
l’associazione riscontrata tra i geni MyD88 e TIRAP e la TB sia un artefatto derivante 
dalla errata strutturazione demografica del campione esaminato. Ad ogni modo, la 
stessa associazione risulta dare risultati contrastanti quando si analizzano differenti 
popolazioni (Nejentsev, Thye et al. 2008, Miao, Li et al. 2011, Sanchez, Lefebvre et 
al. 2012).  Quindi la riproducibilità di uno studio è necessariamente un artefatto? Noi 
pensiamo di no. Nel genoma umano nuovi alleli costantemente si presentano 
creando una vasta eterogeneità che si amplifica ulteriormente con l’interazione tra di 
essi e con l’ambiente. Tutta questa genetica eterogeneità è difficile da rilevare a 
priori e plausibilmente contribuisce all’irriproducibilità degli studi di associazione. 
Inoltre, durante tutta la sua lunga storia evolutiva, il Mycobacterium tuberculosis ha 
sviluppato un’efficace strategia per rendere difficile la sua eradicazione da parte del 
sistema immunitario dell’ospite: la latenza. Questo rappresenta un ulteriore grado di 
difficoltà nel costruire uno studio di associazione con la TB. Sulla base di queste 
considerazioni, il passo successivo è stato quello di disegnare uno studio caso-
controllo scevro dai tutti i principali fattori di “bias” per quanto concerne il 
Mycobacterium tuberculosis. Il primo passo è stato cercare un modello che 
presentasse le seguenti caratteristiche:  
 
- Azzeramento o minimizzazione dei fattori ambientali; 
- Stessa etnia 
- Possibilità di epurare i controlli da eventuali soggetti con TB latente; 
- Un numero consistente di casi e controllo per un’adeguata potenza statistica).  
 
Il modello scelto è stato quello dei bovini per la possibilità di biopsie polmonari al 
punto della morte grazie all’attiva collaborazione tra il laboratorio della Prof.ssa 
Capparelli e l’Istituto Zooprofilattico del Mezzogiorno. In aggiunta, grazie alla 
collaborazione con la Dott.ssa Berisio del Dipartimento di Chimica dell’Università 
di Napoli è stato possibile mettere a punto un “in-house assay” capace di 
discriminare tra batteri attivi e quelli dormienti.  
 
Mycobacterium bovis e diagnosi di infezione polmonare 
 
L’agente patogeno che causa la tubercolosi nei bovini è il Mycobacterium bovis. Nei 
paesi dove i programmi per l’eradicazione della tubercolosi bovina sono operativi 
(test periodici agli animali di allevamento, ispezioni delle carni e pastorizzazioni del 
latte) hanno ridotto a meno dell’1% i casi di tubercolosi umana attribuibile al 
Mycobacterium bovis, circoscrivendola soltanto alle persone affette da HIV o alle 
persone che vantano una prolungata esposizione ad animali infetti (persone del 
settore e veterinari). Il Mycobacterium bovis  ha un ampio range di ospiti, il quale 
include numerose specie di allevamento e selvatiche. Esso è patogeno per l’uomo, 
mentre il Mycobacterium tuberculosis non è patogenico nei bovini (Ocepek, Pate et 
al. 2005). Questa caratteristica potrebbe essere attribuibile alla sola differente 
espressione genica tra di loro (Neill, Skuce et al. 2005) in quanto studi genetici 
hanno dimostrato l’elevata similarità tra le due specie batteriche (circa 99.5% a livello 
nucleotidico) (Garnier, Eiglmeier et al. 2003). Tutte queste osservazioni prese 
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insieme forniscono la plausibilità biologica del ruolo cruciale giocato dal gene MyD88 
anche contro la tubercolosi bovina. Il gene TIRAP non è stato incluso nello studio 
perché la frequenza delle mutazioni risultava essere inferiore a 0.05. 
L’infezione della tubercolosi polmonare può essere di tipo attivo (ATI) o latente (LTI); 
quest’ultima è caratterizzata dalla presenza di batteri dormienti (vitali, ma che non 
crescono sui normali mezzi di crescita) (Oliver 2010). I metodi comunemente usati 
per diagnosticare la tubercolosi sono il tuberculin skin test (TST) o l’IFN-ɣ assay. 
Tuttavia, questi metodi non distinguono tra ospiti ancora infetti e quelli che hanno 
controllato con successo l’infezione (Barry, Boshoff et al. 2009). Presi insieme questi 
gruppi, almeno nel presente studio, avrebbero potuto ridurne sensibilmente la 
capacità discriminante (Schurr 2007).  
 
Results 
 
Diagnosi di casi e controlli 
 
Mycobacterium tuberculosis possiede 5 resuscitation-promoting genes (Rpf) che 
codificano per altrettante proteine (RpfA to RpfE), le quali in forma di proteine 
ricombinanti in Escherichia coli, inducono la risuscitazione del Mycobacterium 
tuberculosis (Biketov, Potapov et al. 2007) e Mycobacterium marinum in vivo ed ex 
vivo (Parikka, Hammaren et al. 2012). Sulla base di questi risultati, è stato sviluppato 
un “in-house assay” capace di resuscitare i micobatteri dormienti attraverso l’impiego 
della proteina RpfB. È stato possibile recuperare micobatteri dormienti dal latte e 
polmoni provenienti da 7 animali trattati con RpfB, mentre nessuna colonia di batteri 
si è avuta dagli stessi campioni non trattati con RpfB. I risultati tra latte e polmoni 
sono stati pienamente concordanti. Altri 20 campioni (latte e polmone) sono stati 
utilizzati per validare l’assay. Il test è stato successivamente esteso a tutti gli animali 
utilizzando campione di polmone collezionati post-mortem. Un test di PCR 
discriminante tra Mycobacterium tuberculosis, Mycobacterium bovis, o 
Mycobacterium avium, ha determinato che tutti i campioni analizzati (con ATI o LTI) 
erano infettati da Mycobacterium bovis.  In conclusione, i casi con ATI sono stati 
trovati positivi alla PCR ed al test batteriologico in assenza di RpfB; i casi con LTI 
sono stati trovati positivi alla PCR ed al test batteriologico in presenza di RpfB; i 
controlli sono soggetti esposti al Mycobacterium bovis (perché provengono dagli 
stessi allevamenti dove sono stati prelevati i casi), ma negativi alla PCR ed al test 
batteriologico sia in presenza che in assenza di RpfB.  
 
Disegno sperimentale 
 
Anche in questo caso lo studio è stato composto da due fasi. La fase preliminare ha 
coinvolto solo 50 animali di controllo, i quali sono stati separatamente confrontati con 
50 casi con ATI o 50 casi con LTI. La fase preliminare ha mostrato una significativa 
associazione del sito polimorfico MyD88 A625C con ATI (P=0.01), ma non con LTI 
(P=0.84). Il sito A625C è situato sull’introne 1 del gene MyD88. Questa fase 
preliminare dello studio ci ha fornito due punti importanti: primo, che l’associazione 
sembra essere abbastanza robusta (poiché è stata rilevata utilizzando soltanto un 
numero piccolo di soggetti) e, secondo, che la stratificazione dei casi (tra la forma 
attiva o latente della TB) potrebbe fornire una maggiore potenza allo studio. Oltre ad 
A625C, non è stata rilevata la presenza di nessuno degli SNPs mostrati nella 
sequenza di riferimento. Per esplorare il ruolo di A625C, sono state allineate 11 
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diverse sequenze del gene di MyD88 appartenenti a diverse specie per studiarne la 
conservazione. Il basso livello di conservazione suggerisce che il sito polimorfico 
A625C non è sotto stringente selezione. Analizzando la sequenza dell’introne 1  con 
SCOPE sono stati evidenziati 4 motivi super-rappresentati nel genoma bovino, i quali 
includono i sito polimorfico. Questa evidenza potrebbe indicare un possibile ruolo 
regolatorio di A625C. Questi dati costituiscono un idoneo substrato per ulteriori future 
investigazioni.  
 
L’eterozigosi ad MyD88 e la resistenza alla tubercolosi attiva bovina 
 
Per la seconda fase dello studio è stato utilizzato un numero più ampio di campioni: 
300 controlli, 150 casi con ATI e 150 casi con LTI, differenti da quelli della prima 
fase. I casi con ATI non sono in equilibrio Hardy-Weinberg (χ2=4.4). Quando il test è 
stato ripetuto con i casi LTI, sia casi che controlli sono in equilibrio (χ2controls =0.9; 
χ2cases = 0.3). I dati suggeriscono un’associazione tra A625C e la ATI, ma non tra 
A625C e la LTI. Primo, il più stringente test esatto di Fisher mostra che l’eterozigosità 
(AC status) è fortemente associata con la resistenza alla ATI (OR 0.19, P=6.0x10-12); 
secondo, l’associazione resta forte anche quando entrambe le classi omozigote (AA 
e CC) vengono unite (OR 0.22, P=1.8x10-10); terzo, il sito A625C non ha influenzato 
la predisposizione alla LTI (OR 0.83, P=0.36 e 0.40). La regressione logistica 
binomiale ha supportato queste conclusioni.  
 
L’eterozigosi ad MyD88 e l’infiammazione 
 
TNF-α, IFN-ɣ e NOS influenzano profondamente la tubercolosi (Scanga, Bafica et al. 
2004). È anche conosciuto che alti o bassi livelli di infiammazione hanno un impatto 
negativo sulla malattia (Glickman and Jacobs 2001, Doherty and Arditi 2004, 
Fremond, Yeremeev et al. 2004). Così, se l’eterozigote ad MyD88 mostrasse un 
livello intermedio di citochine rispetto a quello degli omozigoti, l’associazione tra 
A625C e la resistenza al Mycobacterium bovis acquisterebbe una fortissima 
plausibilità biologica. Per validare questa ipotesi sono stati misurati i livelli di mRNA 
TNF-α, IFN-ɣ e NOS in campioni di polmoni di soggetti con differente genotipo (AA, 
AC, CC) e status (controlli o animali con ATI o LTI) (6 classi; 5 animali/classe). I livelli 
di espressione dei soggetti con ATI o LTI sono stati comparati con quelli dei soggetti 
di controlli aventi lo stesso genotipo. Portatori dell’eterozigosi hanno espresso livelli 
di TNF-α, IFN-ɣ e NOS significativamente inferiori a quelli espressi dagli omozigoti 
AA. Al contrario, gli eterozigoti mostrano livelli solo leggermente superiori a quelli 
espressi dagli omozigoti CC, in questo caso, la differenza non ha raggiunto la 
significatività statistica. Presi insieme questi dati, supportano la conclusione che 
un’ottimale risposta infiammatoria è associata con il fenotipo di A625C. 
 
Discussione e conclusioni 
 
Il presente studio ha dimostrato che nei bovini, animali eterozigoti al sito polimorfico 
MyD88 presentano un rischio ridotto di circa 5 volte di ATI (OR 0.19, P=6.0x10-12). 
Tuttavia, la riduzione del rischio non si estende agli animali con LTI (OR 0.83, P=0.36 
e 0.40). L’eterozigosi ad A625C è associato con livelli intermedi di TNF-α, IFN-ɣ e 
NOS. Lo studio ha anche mostrato differenze nell’espressione di mRNA delle 
citochine tra animali aventi lo stesso genotipo, ma con tubercolosi acuta o latente. La 
differenza è particolarmente evidente negli animali AA. Purtroppo non possiamo 
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attribuire questi diversi livelli di espressione al patogeno o all’ospite, però i livelli di 
citochine rappresentano dei potenziali markers per la riattivazione della malattia. Il 
polimorfismo A625C è locato nell’introne 1 del gene MyD88, questo aggiunge 
evidenza che regioni non codificanti possono influenzare l’espressione genica. Non è 
sorprendente che questo accada nel caso dell’infiammazione, la quale ha bisogno di 
essere soggetta ad una fine e complessa regolazione. Nei bovini, l’esposizione 
ambientale ai micobatteri, che si verificano nella maggioranza dei soggetti, 
interferisce con la diagnosi della TB attraverso i TST o IFN-ɣ assay (Hope, Thom et 
al. 2005). La disponibilità dei reagenti, il tempo di incubazione, ed i livelli di cut-off 
possono influenzare la specificità e la sensibilità di questi assay (Pai, Riley et al. 
2004). Il test batteriologico post-mortem resta, ad oggi, ancora il “gold standard” per 
le diagnosi di avvenuta infezione (Thacker, Harris et al. 2011). La tubercolosi è 
influenzata da molti geni che interagiscono tra di loro (Chang, Linderman et al. 2008) 
e con l’ambiente (Schurr 2007). La presenza del micobatterio è necessaria, ma non 
sufficiente ad acquisire la malattia, come mostrato dai soggetti di controllo (Diamond 
1987). Fattori ambientali (clima, densità dell’allevamento, movimenti del bestiame 
etc.) sono conosciuti come fattori che promuovono la tubercolosi (Neill, Skuce et al. 
2005). Perfino forti effetti genetici sul micobatterio possono essere mancati se non si 
prendono in considerazione gli effetti ambientali (Schurr 2007). Considerevoli OR e P 
value (OR = 0.19; P= 6.0x10-12) riportati in questo lavoro ci rendono cautamente 
ottimisti riguardo la possibilità di approcciare in modo corretto l’analisi genetica di 
questa complessa malattia. I casi sono stati resi omogenei (ATI ed LTI sono stati 
analizzati separatamente), i “confounders” ambientali sono stati o esclusi (sesso e 
razza) o “randomized” (età). Ancor più importante è che i controlli provengono dallo 
stesso allevamento dei casi e restano tuttavia “liberi” dall’infezione (negativi alla PCR 
e test batteriologico) nonostante abbiano avuto la stessa probabilità di infettarsi dei 
casi. Spesso la stratificazione della popolazione è presa in considerazione come 
responsabile dei falsi-positivi ottenuti dagli studi di associazione, ma raramente è 
stata dimostrata essere colpevole (Risch 2000, Colhoun, McKeigue et al. 2003). 
Studi umani hanno mostrato che la stratificazione potrebbe originarsi quando 
differenti etnie sono mescolate (Healy 2006). Nel presente studio è stata studiata una 
sola razza. Ulteriormente, gli stessi risultati provenienti da due campioni di 
popolazioni indipendenti offrono una prova considerevolmente convincente che non 
sia intervenuta alcuna stratificazione. Gli studi di associazione genetica sono 
caratterizzati da un alto tasso di risultati falsi-positivi (Risch 2000). Questa 
conclusione è spesso dovuta alla selezione di un gene candidato senza una 
relazione funzionale con la malattia (Lander and Schork 1994, Risch 2000). Nel 
presente studio, MyD88 è stato selezionato sulla base di un largo numero di 
evidenze sperimentali che mostrano, almeno nel topo, l’importanza di questo gene 
nel “signaling” a valle della rilevazione di componenti del micobatterio e 
dell’induzione degli effettori della risposta immunitaria innata da parte delle cellule 
dell’ospite (Doherty and Arditi 2004, Fremond, Yeremeev et al. 2004). In conclusione, 
l'elevata rilevanza biologica del gene da studiare, la scelta accurata dei criteri 
diagnostici, e la randomizzazione dei “confounders” ambientali, sono stati tutti 
attentamente tenuti in grandissima considerazione durante questo cammino nel 
complesso campo degli studi di associazione. Tuttavia, poiché l'associazione viene 
descritta per la prima volta, i risultati di questo studio sono da considerarsi come 
preliminari. Infine, il test qui utilizzato per distinguere tra malattia attiva e latente 
potrebbe potenzialmente essere esteso alla verifica periodica dei capi di bestiame 
per la tubercolosi. Il conteggio dei micobatteri dormienti risvegliato da RpfB in 
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campioni di latte sarebbe un modo semplice per conoscere l’incidenza della 
tubercolosi latente nella popolazione testata, un parametro fortemente influenzato dal 
controllo del patogeno da parte del sistema immunitario dell’ospite.  
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Introduction 
 
 
Tuberculosis (TB) is 
an infectious disease 
caused by 
Mycobacterium 
tuberculosis (MTB), 
also known as Koch's 
bacillus. It is the 
second cause of 
death from infectious 
diseases in the world, 
after the Human 
Immunodeficiency 
Virus (HIV). In 1993, 
TB was classified as 
a global emergency 
by the World Health 
Organisation (WHO), 
which estimated approximately 9 million of new cases in 2011 and 1.4 million deaths 
due to TB in 84. The same organisation considers Italy one of the Western countries 
where a significant increase in the number of TB cases between 1988 and 1990 was 
observed. Despite the availability of inexpensive and effective treatments, 
tuberculosis is prevalent among the poor people rather than the rich people, in both 
industrialized and developing countries. Almost 60% of total cases of TB are in 
Pakistan, South Africa, China and India. The highest incidence of tuberculosis is 
found in Sub-Saharan Africa, especially in association with HIV infection. The 
alarming increase of tuberculosis is also caused by the outbreak of anti-TB drug-
resistant strains. Further disease spreading-factors are: population growth and 
difficulties to detect and treat cases among the poor masses, disease spreading in 
hospitals and congested 
prisons, and immigration of 
individuals from countries 
where TB is endemic (WHO 
2012).  
People with active TB 
represent the main source of 
infection. Only 10% of 
individuals show signs of 
active tuberculosis within 18 
months from the infection. In 
the remaining cases, the 
host immune response can 
stop the growth of 
microorganism. However, 
the pathogen is eradicated 
in only 10% of cases, 
whereas in the remaining 
90% of the cases, the 
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pathogen is able to evade the antibacterial mechanisms of the host and to survive in 
a non-replicative (dormant) state. This leads to a latent form of tuberculosis Infection 
(LTI), which affects about 2 billion people in the world (Koul, Herget et al. 2004) . 
 
Symptomatology, Diagnosis and Management 
 
Generally TB affects the lungs, although other organs may be involved. The 
development of the disease can occur slowly and symptoms may begin to appear 
months or even years after primary infection. Unlike asymptomatic latent infection, 
actively infected patients  have the following symptoms: 
 
  persistent cough, for more than three weeks (often bloody) 
  high body temperature (above 38ºC)  
 tiredness or fatigue 
 breathlessness 
 lack of appetite and weight loss 
 night sweats  
 
In some cases, TB may occur in extra-pulmonary sites. The incidence of extra-
pulmonary TB varies between 10 and 42% of patients and also varies by ethnicity, 
age, strain of pathogen and the state of the host immune system (Zumla, Kim et al. 
2013). TB infection can affect the lymph nodes, the bones, the joints, the digestive 
system, the bladder, the reproductive system and the nervous system. 
Medical evaluation is needed for people suspected of having tuberculosis, such as:  
 
 People with compromised immune system; 
 People who come from countries where tuberculosis is endemic; 
 People with HIV-infection; 
 People who live or spent time with people with active disease. 
 
The first test used for TB detection is the Mantoux Tuberculin Skin Test (TST). In the 
lower part of the arm is injected a small amount of tuberculin (protein moiety of 
bacillus). Within 48/72 hours the body reaction to the test may appear. A swelling or 
hard area arises around the point of injection, whose intensity of reaction is 
correlated with the exposition to bacteria or the progression of disease. The second 
test is a TB blood test, also known as Interferon-ɣ Release Assay – IGRAs. This test 
measures how strong the person’s immune system reacts to the protein moiety of 
bacillus. The next steps are the smear and the culture of sputum for the presence of 
bacilli and the pathogen DNA amplification. After that, the potentially patient needs 
chest radiograph to estimate the associated pulmonary outcomes. Once assessed 
the severity of infection, pharmacologic therapy is needed. This therapy involves a 4-
drug regimen: Pyrazinamide, Isoniazid, Rifampicin and Ethambutol. When 
multiresistant tuberculosis is suspected, at least 3 of following antibiotics are 
administered, according to drug susceptibilities: Cycloserine, a fluoroquinolone 
(Ofloxacin, Ciprofloxacin and Levofloxacin), Terizidone, Bedaquiline. In extreme 
instances, surgical resection is suggested for the patients with multidrug resistant 
bacilli infection, whose medical outcome is poor.  
Recently, the US Food and Drug Administration approved the use of Delamanid (an 
inhibitor of the synthesis of mycolic acids) in adults, against the infections caused by 
multidrug-resistant Mycobacterium tuberculosis (isionazid and rifampicin). It is the 
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first introduction on the market of an effective drug against TB after the advent of 
rifampicin in the ‘70s (Zumla, Kim et al. 2013). Patients affected by TB and resolved 
after a short period of prophylaxis betray a recurring within 1 or 2 years since the end 
of the drug treatment. This subgroup of individuals shows an increased risk of TB 
reinfection compared to the general population. Thanks to help of DNA fingerprinting, 
it has been shown that there is a new outbreak of TB not due to the failure of 
previous treatment, but to the reinfection of the host by a different bacterial strain 
(Verver, Warren et al. 2005). The main challenge to studying Mycobacterium 
tuberculosis is the lack of a test able to demonstrate the reinfection. The Tuberculin 
Skin Test  and the Interferon- ɣ Release Assay cannot distinguish reinfection by the 
awakening of a latent infection (Andrews, Noubary et al. 2012). 
 
Mycobacterium tuberculosis 
 
Mycobacterium tuberculosis is a member of a group named Mycobacterium 
Tuberculosis Complex (MTBC). At this group belong 6 other genetically related 
species (considered as a sub-species): M. bovis, M. africanum, M. microti, M. 
pinnipedii, M. caprae and M. capretti. Although all these strains can cause 
tuberculosis, they have different phenotypic traits and different host range (Cole, 
Brosch et al. 1998). 
MTB is an aerobic bacterium characterized by slow growth and size of 0.2-0.6 µm. It 
is generally rod-shaped, without flagellum, although its shape may vary depending on 
the environment. In a study of 1940, the authors had demonstrated the different 
forms assumed by MTB under unfavourable environmental conditions (reduced 
supplement in the culture medium, low quantity of oxygen, etc.) (Vera and Rettger 
1940). To date, by advanced microscopy techniques (SEM, TEM, etc.) it has been 
confirmed that Koch’s bacillus can assume 
different form from the classic rod-shaped. The 
wall of MTB is the main factor involved in the 
environmental changing. MTB complex structure 
provides resistance to many antibiotics and 
unfavourable environmental conditions. Starting 
from the inside, cell membrane is made up of 
several layers of peptidoglycan (PG), 
arabinogalactans (AG), lipomannans (LM), 
mannose- lipoarabinomannans (ManLAM) and 
mycolic acids (MA). All this layers are covalently 
linked one to each other forming a very complex 
structure. The PG consists of long chains of N-
acetylglucosamine (NAG) linked to the chains of 
muramic acid (NAM) through the residues of L-
alanyl-D-iso-glutaminyl-meso-diaminopimelic 
acid (DAP) (Velayati, Farnia et al. 2012). The 
long chain polysaccharides (LM, AG and LAM) 
form a bridge between the peptidoglycan and the 
mycolic acids, which are long chain fatty acids 
and the main component of the wall of MTB . 
The complex structure of the membrane gives to 
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the mycobacterium the singular colouring properties. These properties (acid-alcohol 
resistance) allow seeing the MTB through Zhiel-Nielsen (bright field) and Auromina-
rhodamine (fluorescent field) stains. 
 
Mycobacterium tuberculosis and its history 
 
MTB has plagued the 
mankind since 
immemorial times. 
Probably, it is the 
bacterium that has killed 
more people than any 
other microbial pathogen. 
Its low rate of mutation  
allowed some scientists to 
suppose that the "genus 
Mycobacterium" might 
date 150 million years ago 
(Hayman 1984). All of the 
modern members of the 
Mycobacterium Complex 
(M. bovis, M. africanum, 
M. microti, M. pinnipedii, 
M. caprae and M. capretti) 
seem to be descended from a common ancestor from Africa dating back to about 
35,000-15,000 years ago. First physical traces of MTB were found in Egypt and 
dated about 5,400 years old. In young Egyptian mummies was found the presence of 
typical skeletal deformities due to tuberculosis infection (Pott's disease). The advent 
of modern techniques for amplification of bacterial DNA from tissues did not left 
doubt about the cause of the skeletal deformities. Also, there are some clear 
references to tuberculosis in the biblical books like Deuteronomy and Leviticus. Well 
established in East Africa, tuberculosis began to spread in Europe and Asia thanks to 
migration of small groups of individuals between 35,000 and 89,000 years ago. It was 
found writings on tuberculosis dating back to 3,300 years ago in India and 2,300 
years ago in China. As in Egypt, even in Peruvian mummies it was possible to 
observe the bone structure deformity due to mycobacteria infection. In Europe, the 
earliest writings date back to Hippocrates who defines tuberculosis with name 
"Phtitis" and emphasizes the preference of the disease for the young men. After the 
fall of the Roman Empire, the writings on tuberculosis seem to disappear. This does 
not mean that tuberculosis was not present. Archaeological findings dating to the fifth 
century after the fall of the Roman Empire indicate that tuberculosis was widespread. 
In 1266, the 44 years old St. Francesco of Assisi died of tuberculosis. Three 
centuries later, the French physician René Laennec (1781-1826), inventor of 
stethoscope, added significant evidence to the knowledge about tuberculosis. In his 
book "On Mediate Auscultation”, the author clearly defines the pathogenesis of the 
disease and the concept of pulmonary and extra-pulmonary tuberculosis. He also 
describes many of the physical signs of lung disease still used today. After the 
“Laennec’s era”, TB inundated Europe as a real tsunami, with peaks of 800-1,000 
deaths per 100,000 people in London, Stockholm and Hamburg. In the Northern part 
of Europe, TB has been classified as hereditary disease, while in the Southern part 
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as infectious disease. In 1865the French military surgeon Jean-Antoine Villemin 
provided evidence of the infectious nature of TB by inoculating a rabbit with a small 
amount of purulent fluid resulting from the lungs of a man who died of tuberculosis. 
Although the rabbit apparently looked like healthy, the lungs showed extensive signs 
of illness when sacrificed 3 months after inoculation. In 1882, the history of 
tuberculosis changed forever when Robert Koch presented his work "Die Aetiologie 
der Tuberculose" in Berlin. On that occasion, Robert Koch demonstrated that it is a 
bacillus which causes tuberculosis, and dictated the points of Koch's postulate that to 
date provide the gold standards for the classification of the infectious etiology of a 
disease. Also, Koch discovered in the body of living individuals a compound 
originated from the same bacilli, which rendered harmless the pathogen. The 
injection of this substance, called tuberculin, spread rapidly as a treatment against 
tuberculosis, but shortly after it was discredited as ineffective. Robert Koch injected 
himself with 0.25 cm3 of tuberculin which caused him powerful fever. So he 
understood the diagnostic power of the tuberculin. In 1908, Charles Mantoux 
introduced the use of a needle and a syringe to inject tuberculin under the skin. In 
1909, Von Pirquet, a Viennese pediatrician, after trying on himself the effects of 
tuberculin, published a work on the subcutaneous tuberculin injection used as a 
vaccine in children. He fixed the cut- point of 5 mm for the positive tuberculin reaction 
in children who did not exhibit signs of tuberculosis and he was the first person to 
coin the term latent tuberculosis. In the '20s, the Norwegian physicist Olaf Scheel 
noted the high incidence of TB among nursing students in their first year of clinical 
training. After 1924, Scheel, along with his colleague Heimbeck, performed the 
Tuberculin Skin Test (TST) on all of nursing center students, before the moment of 
entry to their training (Bjartveit 2003). After their three years training they noted a 
high incidence of infection and disease among the TST-negative students. 
Afterwards, this study was replicated in many hospitals in Europe and the United 
States of America. The high rate of infection and lack of treatments for latent 
tuberculosis (LTBI) allowed researchers to conduct an observational study, which 
could not be executed today (Andrews, Noubary et al. 2012). Shortly after the 
American biochemist Florence Seibert sinthesized purified the protein (PPD) that to 
date is still used as the standard test for TB. In 1952, Carroll Palmer and Leroy Bates 
used the PPD to conduct a study involving 3,000 patients with tuberculosis. Only in 
1% of cases, the reaction to PPD by the immune system did not occur. Three years 
later, the WHO extends this skin test in children attending schools in various 
countries. This study brought to light that in countries with high prevalence of 
tuberculosis, such as Ethiopia and the Philippines, a large number of schoolchild 
without any symptoms of the disease showed a reaction to PPD similar to that of 
patients with active tuberculosis. These children were affected by latent tuberculosis, 
noted for the first time by Von Pirquet. A few years later, Edwards and Palmer 
performed the TST on 600,000 American soldiers. They concluded that latent 
tuberculosis was common in the United States of America and presumably also in 
other regions with low incidence of tuberculosis. While knowledge about tuberculosis 
was implemented through the efforts of Koch, Von Pirquet and other scientists, 
mortality rates began to decline in the mid-nineteenth century. The causes can be 
attributed to the improvement of social and living conditions and to the selection in 
breeding of species/populations genetically more resistant to the TB. The decline of 
tuberculosis continues to date, largely fought by the public health and the discovery 
of more effective drugs. The incidence of tuberculosis in Europe and America is 
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historically low. By contrast, in Sub-Saharan Africa, TB continues unopposed, 
strongly fueled by AIDS (Daniel 2006). 
 
Transmission of Mycobacterium tuberculosis infection 
 
MTB infection starts with 
inhaling droplets containing 
the pathogen (size 1-6 µm), 
expectorated by patients with 
active tuberculosis after 
strong coughs. Many factors 
are involved in the risk of 
infection including the 
proximity to the patient, the 
inhaled bacterial load, the 
host immune system, and the 
genetic predisposition of the 
host. The droplets nuclei 
reach the alveoli of the lungs 
trough nasal/mouth passage. 
Their small size allows 
penetrating the upper 
respiratory tract where many 
organisms are removed by 
mucociliary mechanism. Here, 
the droplets containing 
pathogens are intercepted by 
phagocytic antigen-presenting 
cells (APC) such as dendritic 
cells and alveolar 
macrophages. Some studies 
report also the involvement of non-professional phagocytes cells (Bermudez and 
Goodman 1996, Garcia-Perez, Mondragon-Flores et al. 2003). The Pathogen-
Associated Molecular Patterns (PAMPs) are recognized by specific MTB Pathogen 
Recognition Receptors (PRRs) located on the surface of the cells of the host immune 
system. These receptors, including Toll-like Receptors (TLRs), are essential to 
initiate and coordinate the innate immune responses of the host (Jo, Yang et al. 
2007). The interaction between PAMPs of MTB and TLRs of the host triggers a 
signal transduction cascade that culminates in an inflammatory response by the host 
immune system (Harding and Boom 2010). However, mycobacteria have developed 
effective strategies to modulate or even inhibit this response. The most important 
ligands on the surface of the MTB that interact with TLRs are: 19 kDa lipoprotein, the 
lipomannans (LM) and the mannose-lipoarabinomannans (Jo, Yang et al. 2007). The 
interaction between these ligands with TLRs leads to the activation of the nuclear 
transcription factor B (NF-kB) and the consequent production of pro-inflammatory 
cytokines such as tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-ɣ) 
and nitric oxide. The NF-kB activation involves the myeloid differentiation primary 
response protein 88 (MyD88) -dependent and -independent pathways (Yamamoto, 
Sato et al. 2003, Jo 2008). In mice, prolonged exposition of alveolar macrophages’ 
membrane to the MTB 19kDa lipoprotein attenuates the antigen processing, which in 
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turn reduces the expression of the major histocompatibility complex (MHC)-II, 
dampening T cell recruiting. In this way, a subpopulation of infected macrophages 
with a modulated APC function constitutes an invisible niche to the host immune 
system. Here, the bacteria survive, resist and sometimes proliferate. However, some 
other strategies are adopted by MTB to evade immune system’s surveillance. The 
most studied is the effect of Man-LAM upon maturation of the phago-lysosome and 
the production of reactive nitrogen intermediate (RIN), lethal for MTB (Kang, Azad et 
al. 2005). 
 
Latent Infection of Mycobacterium tuberculosis 
 
The alveolar macrophages, after the entry of MTB, produce pro-inflammatory 
cytokines and chemokines as alarm signal for the host immune system. Thus, 
lymphocytes, monocytes and neutrophils can migrate to the site of infection. Despite 
well-orchestrated, sometimes the immune response could be insufficient. Some 
bacilli are able to evade the countermeasures of the immune system and multiply 
inside the cells causing necrosis (Chen, Gan et al. 2006).  While T cells (CD4+ and 
CD8+) rush to the site of infection, engulfed dendritic cells migrate to the closest 
lymph node causing potential dissemination. Cytokines produced by T cells may 
contribute in a multitude of ways to the clearance of bacteria, including the activation 
of macrophages where the MTB resides. Specific structures called granuloma 
enclose the infection when it becomes chronic. These granulomas consisting of 
lymphocytes (CD4+, CD8+ and B cells) that surround macrophages, fibroblasts and 
other cells engulfed of bacilli. The function of the granuloma is to limit the spreading 
of the infection from the lung creating, in this way a local microenvironment of action 
for the cells of the immune system. Unfortunately, MTB has developed effective 
strategies to survive under these adverse conditions. The host immune system is not 
able to recognize the Bacilli in non-replicative state (dormancy), characterized by low 
metabolic status. Recent studies have shown physiologically different type of 
granulomas in different individuals. Some of these suppress the MTB (sterilizing 
immunity), while some others promote the persistence of viable bacilli in this 
environment (Young, Gideon et al. 2009). However, without formation of granuloma, 
the MTB could not be contained and could spread more rapidly in other organs. In 
HIV-infected patients (deficient of granuloma formation), TB appears to be more 
aggressive than people without HIV  (Russell 2007). Cynomolgus macaques infected 
with a low dose of MTB lead to the formation of at least two types granulomas. 
Histopathological studies have shown the classic granuloma formed by epithelial 
macrophages, neutrophils and other immune system cells surrounded by fibroblasts, 
while the other type of granulomatous lesions, already seen in human latent TB, are 
composed almost exclusively by fibroblasts which contain few macrophages (Via, Lin 
et al. 2008, Lin, Rodgers et al. 2009). To date, no one knows if the MTB is located 
within macrophages or within the fibrotic tissue. If the host immune system is 
compromised, the dormant bacilli present in the granuloma can resuscitate during 
host’s lifespan.  
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Resuscitating-promoting factor proteins  
 
One-third of worldwide population suffers of tuberculosis infection. Only 10% of 
people show active signs of TB, while the remaining of infected people carry the 
pathogen in dormant form.  TB pathogens have the ability to assume a non-
replicative state after strong host immune response or post-drug treatment and, then, 
they are capable to resuscitate upon immune suppression or spontaneously 
(McCune, Feldmann et al. 1966, McCune, Feldmann et al. 1966). The reactivation of 
the mycobacterium is contributed by five secreted proteins named Resuscitating-
promoting factors (RpfA-E). The hydrolyzing activity of these proteins on the 
peptidoglycan of bacterial cell wall allows the transition of mycobacteria from the 
dormant state to the viable one. Aged mycobacterial cultures have shown greater 
sensitivity than viable MTB to the exogenously administration of Rpf proteins in vitro 
(Shleeva, Mukamolova et al. 2004). A physiologically role of these proteins, 
especially under bacterial stress condition, was confirmed in various in vivo and ex 
vivo animal models (Biketov, Potapov et al. 2007, Parikka, Hammaren et al. 2012). 
The Resuscitation-promoting factor B (RpfB) is the most complex and studied protein 
dedicated to bacterial reactivation (Ruggiero, Tizzano et al. 2007). The 
understanding of the molecular mechanism behind the transition from non-replicative 
to viable state could help the global strategy to prevent the spread of TB. 
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Vaccine strategies and Bacilli Calmette-Guérin  
 
MTB has an extraordinary ability to hide itself within the host immune system cells. 
This ability makes inadequate most of vaccine strategies, for example those ones 
based on the neutralisation of virulence proteins or genes. Another strategy for 
vaccine development introduces in the host an avirulent bacterium that triggers 
immune response, but not the disease. To date, numerous laboratories are focusing 
on the development of attenuated strains of MTB through genetic manipulations. 
Mycobacterium bovis bacilli Calmette-Guérin (BCG) is unable to cause disease in the 
human and, until today, it is the current vaccine administered in infants at birth in 
countries where the TB is endemic. BCG vaccine shares ample homology with MTB 
(<95%), and has protective effects against disseminate TB in children. Unfortunately, 
BCG vaccination seems to be inadequate because it does not prevent primary 
infection and reactivation of latent pulmonary infection (WHO 2012). In 1908, at the 
Institute Pasteur de Lille in France, a physician, Albert Calmette, and the veterinary 
Camille Guérin noted that bacilli cultured in glycerinated/beef/bile/potato medium had 
lost their own virulence. After 13 years and over 200 subcultures later, the bacilli 
were attenuated enough to be considered for use as a vaccine. In 1921, after the 
World War I, both scientists were ready to try the vaccine. Over the next 7 years, 
more than 100,000 children were immunized and BCG was widely accepted in the 
most part of Europe. More than 30 vaccines, all as primary immunogens to replace 
BCG and as boosters for BCG, are in development or have entered in clinical trials 
(Raviglione, Marais et al. 2012). Understanding the molecular mechanisms behind 
the persistence of MTB inside the cells, the recruitment and the activation of T and B 
cells in the site of infection, and the host genetic resistance are important keys for the 
development of an effective vaccine against TB.  
 
Activation of inflammation through MyD88 and TIRAP 
 
The inflammation is a complex biological mechanism involved in response to different 
harmful stimuli. It is the effort of the mammalian body to restore damaged cells, 
tissues or organs. The inflammation is triggered by activation of many receptors 
located on the surface of the cells. The most studied receptors are the Toll-like 
receptors (TLRs). They were discovered for the first time in Drosophila melanogaster, 
where they are involved in the formation of dorso-ventral patterning of embryos 
(Hashimoto, Hudson et al. 1988). Later, it was discovered that flies mutant for this 
receptor were very susceptible to fungal infections (Lemaitre, Nicolas et al. 1996). 
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TLRs homologues have been 
found also in mammals and 
are able to recognize specific 
microbial patterns conserved 
among the pathogens. The 
activation of signaling 
pathways via TLRs triggers 
several genes involved in 
immune response. TLR 
family comprises 11 
members (TLR 1-11) in both 
human and mouse. Each 
TLR shows specific 
responses to the microbial 
component involving specific 
molecules from the cell’s 
surface to the nucleus. One 
of these molecules is a 
common adaptor called 
MyD88, which was the first 
essential component 
characterized for the 
induction of inflammatory 
cytokines (TNF-α and IL-12). TLRs signaling pathways initiate when the cytoplasmic 
portion of TLRs, named Toll/IL-1 receptor domain (TIR), interacts with the TIR 
domain of MyD88. Activated MyD88 recruits IL-1 Receptor-Associated Kinase (IRAK) 
and then the TNF Receptor-Associated Factor 6 (TRAF6). TRAF6 triggers two 
distinct pathways: c-Jun N-terminal Kinases (JNK) and Nuclear Factor-kB (NF-kB) -
MyD88-dependent pathways, that lead to the transcription of several pro-
inflammatory genes. Mice knockout for MyD88 did not show production of pro-
inflammatory cytokines and activation of NF-kB and JNK upon activation of TLR2, 
TLR7, and TLR9. However, mice stimulated with LPS display activation of NF-kB and 
JNK, although without production of cytokines (Kawai, Adachi et al. 1999).  Following 
studies show without doubts that there is a MyD88-independent pathway 
downstream the activation of TLRs. In this pathway, LPS stimulation activates 
Interferon Regulatory Factor 3, a transcription factor of several IFN-inducible genes. 
Later, the analysis of the MyD88-independent pathway has allowed to identifying 
another TIR domain-containing Adaptor Protein (TIRAP) or MyD88-adaptor-like 
(Mal). Similarly to MyD88 knockout mice, TIRAP knockout mice displayed 
compromised pro-inflammatory cytokines production and delayed activation of NF-kb 
and JNK. Further studies clearly established that TIRAP plays a crucial role in the 
MyD88-dependent signaling pathway via TLR2 and TLR4 but not in the MyD88-
independent signaling activated by TLR3, TLR5, TLR7, and TLR9 ligands (Takeda 
and Akira 2004).  
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Case-control study 
 
A case-control study is a 
statistical method designed to 
identify potential risk factors. In 
this type of study two groups of 
people are identified by referring 
their health status: the cases are 
people with the disease or the 
condition of interest and controls 
are people with no history of 
disease or without the condition 
of interest. Usually, a case-
control study is cheap, quick and 
performed as initial assessment 
before undertaking larger and 
more expensive studies. Case-
control studies are not 
susceptible to loss  during the 
follow-up.  Cases and controls 
are compared to establish 
whether a particular risk factor is 
more frequent in one group than 
in the other. The most commonly 
measure of this frequency 
measured between the exposure 
(+/- Risk factor) and outcome (+/- disease) is called odds ratio (OR). In other words, 
OR determines whether a risk factor is associated or not with a particular disease 
and compares the magnitude of that association. The OR must be accompanied by 
95% Confidence Interval (95% CI) that estimates the accuracy of the OR. To note, 
the 95% CI, in contrast to p value, is not a measure of statistical significance. Often, 
many risk factors are not measured and can influence the OR in case-control studies. 
These risk factors are called confounding and, when unequally distributed between 
the groups, can distort the association between the exposure and the condition of 
interest. To minimise the effect of confounding factors the OR can be adjusted using 
a statistical method known as logistic (or binomial) regression. Unlike in linear and 
multiple regression analyses, where the outcome variable is continuous, in logistic 
regression it is binary (yes or not). Generally, the predictor variables (age, gender, 
etc.) are any combination of binary, continuous, or categorical variables, independent 
of each other. The logistic regression assesses the association between a dependent 
variable (disease or outcome) and one or more predictor variables concurrently. The 
results of logistic regression are presented as unadjusted and adjusted odds ratios 
for potential confounding effect of predictor variables. That means the measure of 
association between the disease and a dependent variable when all other dependent 
variables are constant. The extent of confounding is determined by comparing of the 
unadjusted and adjusted OR. The explanatory variable is defined independently 
associated with the medical condition when the association is significant after 
adjustment for confounding. Another value is also estimated with logistic regression: 
the coefficient of regression (β). The exponential function of β (eβ) corresponds to the 
OR associated with one unit increase in the value of exposure. The potential 
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confounding effect can be minimized more efficiently by reducing the systematic 
differences between the groups (matching cases and controls) at the design stage of 
the study, rather than in the subsequent statistical analysis.  
 
Aim 
 
Only 10% of total infected people will 
develop active TB.  At the base of the 
susceptibility of disease there are the 
interactions of host’s genetics with 
environmental factors and the 
pathogen.  Understanding these 
interactions represents a huge 
challenge facing human genetics. 
Schurr wondered if the susceptibility 
to tuberculosis  was acquired or 
inherited (Schurr 2007). The author 
knew very well that tuberculosis  
could develop only upon exposure to 
the pathogen. With  his question 
(posted as the title to the article), 
Schurr intended to highlight the 
essential role of the hereditary 
component for resistance to 
tuberculosis.  
The host’s membrane receptors TLRs 
recognize many PAMPs of MTB and, 
through adapter proteins, lead to the 
activation of nuclear factor kB and the 
successive immune response, innate 
and adaptive. The detection of mycobacterial DNA requires TLR9 and MyD88; 19LP, 
LM, LAM and STF requires TLR2 and MyD88, whereas HSP65 requires TLR4, 
MyD88 and Toll-Interleukin-Receptor Adapter Protein (TIRAP). Mice knockout for 
MyD88 show a low production of TNF-α, IL-12 and NO in response to the infection of 
MTB and die  by 4 weeks (Fremond, Yeremeev et al. 2004). Instead, Mice knockout 
for TIRAP control effectively MTB infection (Fremond, Togbe et al. 2007). MyD88 and 
TIRAP have a clear biological plausibility. In addition, both work as transmitters of the 
signal from the receptors of the TLR family to the transcription factor NF-kB. 
Therefore, their location on separate chromosomes (independence) and their 
common function (signal transmission) make it plausible the hypothesis that these 
genes interact between them. If the above proposition is correct, the study could 
provide an example of epistasis (interaction between independent genes). The Single 
Nucleotide Polymorphism (SNP) C558T of TIRAP is associated with the susceptibility 
to meningeal tuberculosis (Hawn, Dunstan et al. 2006, Caws, Thwaites et al. 2008) 
and, again, the same SNP studied in this work (rs81777374) confers protection 
against malaria and tuberculosis (Khor, Chapman et al. 2007). Following studies, 
however, do not confirm the protective role of S180L against tuberculosis (Nejentsev, 
Thye et al. 2008, Miao, Li et al. 2011). One more study shows that neither TIRAP 
(rs352165 and rs352167) nor MyD88 (rs4988457 and rs6767684) influence 
tuberculosis (Sanchez, Lefebvre et al. 2012). In the light of these discrepancies 
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emerged from the study of these same genes in different populations, even studying 
the same SNP (rs81777374), it was decided to investigate the role of these genes in 
patients with pulmonary tuberculosis in the Italian population.  
 
Premise  
 
The present study analyses the same disease (tuberculosis) in two different species, 
humans and cattle. The study however should not be intended as consisting of two 
independent investigations or - worse – as the duplication in cattle of the study 
originally carried out in humans. The studies in humans and cattle should be seen as 
tightly linked, rather than independent. The study in humans necessarily preceded 
that in cattle. Tuberculosis – in humans as well as in cattle – can assume the active 
or latent forms. The genes chosen for study (MyD88 and TIRAP) could differently 
influence the two forms of the disease. However, patients enrolled in case-control 
studies need to be highly homogeneous (all with the same disease form). Mixing 
cases with latent and active tuberculosis infection would have sensibly reduced the 
power of the study or, worse, open the way to type I errors and false results. 
Currently there are no methods that can discriminate between the two forms of 
tuberculosis with the level of accuracy required by the kind of study we planned to 
carry out. We therefore were forced to set up an assay able to distinguish between 
active and latent infection. To do this we needed lungs biopsies. These specimens 
could be obtained only from cattle, at the time of slaughter. The assay demonstrated 
that, at least in cattle, the genes influence the active –but not the latent – form of 
infection.  
 
Results 
 
Study design 
 
To reduce the type I error and to limit multiple comparisons, it was chosen a study in 
two phases. In the first phase of the study (hypothesis - generating) 100 cases and 
100 controls were recruited and genotyped for the polymorphic sites on MyD88 and 
TIRAP genes. The site rs8177374 on TIRAP was included in the study because in 
the literature there are conflicting results, the rs6853 was chosen because it was the 
only one among the 5 tested to show an allele frequency > 0.05. Both sites showed 
statistically significant association with the disease (P-value < 0.05) (Table 1). Based 
on these preliminary results (MyD88: OR 0.40 and a proportion of controls with 
susceptible genotypes 0.61; TIRAP: OR 0.48 and a proportion of controls with 
susceptible genotypes 0.64), it was calculated that a sample of 185 cases and 185 
controls for MyD88 and another one of 313 cases and 313 controls for TIRAP would 
be necessary to assuring to the study a statistical power of 96%, with a significance 
level of 0.01. In the second part of the study 400 cases and 400 controls were 
involved (independent from the cases and controls used in the preliminary phase of 
the study). In order to get a cohort as homogeneous as possible, the cases were 
recruited only among patients with evident pulmonary TB, confirmed by chest X -ray, 
bacteriological tests and PCR. The bacteriological tests were performed on sputum 
samples. All cases were treated by Monaldi Hospital (Naples), the reference center 
for tuberculosis of the southern part of Italy. Controls were selected among wives, 
husbands and friends of patients without any clinical evidence of tuberculosis 
(negative test with interferon-ɣ). In that way, controls are not infected and genetically 
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unrelated to the cases, despite the exposure to Mycobacterium tuberculosis (> 2 
years). The criteria used to classify cases and controls were the same in both phases 
of the study. Cases and controls were collected in more than five years of 
collaboration between the Hospital and the laboratory of Prof. Rosanna Capparelli. At 
that time six controls became positive to test with interferon and were excluded from 
the study. The cases consisted of 258 males and 142 females (mean age 50 ± 19 
years), the controls of 222 males and 178 females (mean age 49 ± 17 years). The 
study was approved by the Ethics Committee of Monaldi.  
The informed consent to the study was obtained from all patients who participated to 
the study. 
 
Heterozygosis is associated with protection against pulmonary tuberculosis  
 
The genotype frequencies of the markers rs6853 and rs8177374 were in Hardy- 
Weinberg equilibrium among the controls, but not among the cases (Table 2). The 
association of polymorphisms was confirmed by Fisher's exact test (Table 2). 
Heterozygous status (AG for MyD88 and TIRAP CT) has been associated with 
resistance to pulmonary tuberculosis for both loci. The protection persists when the 
two homozygous classes are pooled (AG vs. AA + GG and CT vs.  TT + TT) (Table 
2). Age is known as a risk factor for pulmonary tuberculosis. Therefore, ORs 
associated with different genotypes (age confounding effect) were corrected by the 
Mantel-Haenszel test (Table 3). After correction, the double heterozygous 
(MyD88/TIRAP AG/CT) still offer high level of protection (OR 0.16) compared with 
single heterozygous (AG: OR 0.4, CT: OR 0.42) (Table 3). To assess how to age-
related risk varies across the “strata”, the data were re-analyzed using the logistic 
regression model. The analyses were restricted to only the groups with a number of 
individuals of ≥45. Apart from the category 31-40 vs. 21-30 years (apparently 
protected, OR 0.31), the model showed that the risk of developing the disease 
increases with age, as shown by the increase in ORs (1.32 to 13:59) (Table 4). 
Clearly, the age and the possible variables associated with age, such as smoking, 
diabetes and prolonged exposure to the pathogen, can overcome the resistance 
conferred by genes. We did not have access to all patient records and therefore we 
could not investigate the role of these potential "confounders". The logistic regression 
model was also used to dissect the contribution of each genotype and their 
interaction with the ORs. Particularly evident was the interaction between the AG and 
CT genotypes (OR estimated 0.09), and the interaction, although in the opposite 
direction, between the GG and TT genotypes, AA and CC, and AA and CT (OR 5.78, 
5.78 and 7:46 respectively) (Table 5). 
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The association resists to the demographic stratification 
 
The study was extended to one sample of population from Romania and one from 
Ukraine. The study, although underpowered, confirmed the protective role of the 
state of heterozygous to the site MyD88 rs6853 (P= 0.003-0.004) and the site TIRAP 
rs8177374 (P= 0.01 to 0.02) (Table 2). The protective role provided by heterozygous 
status persisted when the samples from Romania, Ukraine and Italy were mixed (P = 
8x10-13, rs8177374 P= 5.3x10-10) (Table 2). The association of rs6853 and rs8177374 
with pulmonary tuberculosis extended to three nationalities tested in this study 
resisted to the artificial stratification determined by the pooling different ethnicities. 
 
The heterozygous controls inflammation 
 
To investigate the mechanism of how the host controls the infection depending on 
genotype basis, Peripheral Blood Mononuclear Cells (PBMCs) from healthy blood 
donors (controls) (nine genotype groups; 5 samples/group) were extracted. PBMC 
were stimulated with heat-killed Mycobacterium tuberculosis strain (H37Rv). The 
levels of TNF-α, IFN-ɣ and NO (nitric oxide) released into the medium were 
measured by ELISA test. In the context of the AA genotype, the CT subjects showed 
intermediate levels of TNF-α, IFN-ɣ and NO compared with the CC and TT subjects. 
In the context of genotype AG, the data show the same trend, although some 
differences are not significant. Furthermore, the lowest levels of cytokines were 
observed in subjects GG, as if possessing the allele "A" facilitates the production of 
cytokines and the allele "G" to reduce it. These data indicate that heterozygotes are 
associated with an intermediate level of cytokines and NO (Figure 1). The 
experimental data were then analyzed with a generalized linear model. This 
methodology allows us to study the relationship between a variable (in this study, 
TNF-α, IFN-ɣ and NO) and a set of predictors (MyD88 and TIRAP) to extract a 
model. In addition, this methodology can be applied to data that presumably do not 
have a normal distribution (like in this case, where only a small number of donors 
were recruited). The model calculate β1, β2 and β3, which measure as MyD88, 
TIRAP and MyD88-TIRAP interaction influence the levels of TNF-α, IFN-ɣ and NO 
released. Surprisingly, the model predicted the cytokine levels on the basis of their 
genotypic structures with exceptional accuracy (Table 6). These results suggest that 
the two loci cooperate strongly to control the disease. This evidence is strongly 
supported by the evidence that TIRAP and MyD88 form heterodimers. 
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In silico analysis of both polymorphic sites 
 
The site rs6853 is located on three prime Untranslated Region (3' UTR) of the MyD88 
gene. Comparison of different genome sequences revealed that both alleles A and G 
are conserved in many species, suggesting that they are maintained, or at least 
tolerated by natural selection (Figure 2). The analysis with 4 ENCODE tracks showed 
that the 3' UTR of the polymorphic site could have effect on interaction between the 
MyD88 mRNA and other protein factors. The residing of rs8177374 site on exon 5 of 
the gene TIRAP has allowed us to evaluate whether the change of a serine with a 
leucine at position 180 may have an impact on the structure of the protein. Both 
amino acids are represented in position 180 of the TIRAP genes of 22 species of 
mammals and through SIFT algorithm has been predicted that both are compatible 
with the activity of the protein (Figure 3). These results suggest that the isoforms A 
and B originate from the same mRNA molecule that has undergone alternative 
splicing (Figure 4), giving a further biological plausibility to the polymorphism. 
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Discussion and Conclusion 
 
Very little is known of the "crosstalk" between genes involved in the resistance to the 
pathogen. In this study, it was investigated how MyD88 and TIRAP genes influence 
each other in the pulmonary tuberculosis. The hypothesis that the two genes may 
interact seems plausible because both proteins MyD88 and TIRAP are involved in 
the "signalling" downstream of TLRs. Also, it was demonstrated that the two genes 
cooperate or antagonize each other on the basis of their allelic combination. The 
heterozygosis at both loci provides a stronger protection (P= 1.3x10-12, age-
corrected, Table 3) compared to a single locus heterozygous (P= 7.8x10-8 MyD88, 
TIRAP P= 2x10-6, Table 2). At the same time, in individuals AG/TT (MyD88/TIRAP) 
the TT genotype neutralizes protection afforded by the AG genotype (Table 5). These 
data, although in a limited way, show how two or more independent genes may 
contribute to the formation and regulation of the same phenotype. Individuals 
heterozygous at MyD88 or TIRAP loci show intermediate levels of TNF-α, IFN-ɣ and 
NO compared to other genotypic classes (Figure 1). These molecules play a crucial 
role against the Mycobacterium tuberculosis infection (Casanova and Abel 2002, 
Velez, Hulme et al. 2009). NO exerts a strong anti-mycobacterial activity and, 
together with TNF-α, promotes the formation of granulomas (Miller and Ernst 2009). 
IFN-ɣ induces the production of NO, the expression of MHC II molecules and antigen 
presentation (Fortune, Solache et al. 2004, Scanga, Bafica et al. 2004). Furthermore, 
there are a lot of evidence that the over-expression of these molecules favours the 
tuberculosis. Many of the symptoms are caused by host’s immune response, rather 
than by Mycobacterium tuberculosis (Glickman and Jacobs 2001). Indeed, 
reactivation of TB was observed after therapeutic treatment with TNF-α (Mankia, 
Peters et al. 2011) or in patients with HIV infection after antiretroviral treatment 
(French and Price 2001). Even the hypo-expression of TNF-α, IFN-ɣ and NO 
promotes TB. The biological advantage to have an intermediate level of expression 
of these molecules becomes clear. This advantage is much more pronounced in the 
double heterozygotes (Table 5), showing that the crosstalk between genes extends 
from the epidemiology to the molecular level. The advantage expressed by 
heterozygotes suggests that the allele frequencies at polymorphic sites of rs6853 and 
rs8177374 are maintained by balancing selection, where homozygosis is associated 
with pulmonary tuberculosis and heterozygosis with resistance. In agreement with 
this hypothesis is the fact that both polymorphic sites are conserved through 
speciation (Figures 2 and 3). In conclusion, the association of rs8177374 and rs6853 
with pulmonary TB seems promising on Italian samples, but should be confirmed in 
future studies. 
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Aim II 
 
This kind of study revealed itself much trickier than expectations and, unfortunately, 
association studies lack of reproducibility (Ioannidis, Ntzani et al. 2001). During the 
first phase of the study we ran into different obstacles. In order to minimize all 
sources of error the study was built on specific points:  
 
- Independent findings replication (Two-steps study);  
- Low P-value (10-6-10-8);  
- Selection of homogenous cases (the study enrolled patients with active 
pulmonary tuberculosis confirmed by X -ray chest, PCR and bacteriological 
positivity); 
- Use of appropriate controls (individuals negative to the IFN-ɣ assay, but 
exposed to the pathogen and genetically unrelated to the cases).  
 
Furthermore, the evidence that the association is maintained in 3 different ethnic 
groups (Table 2) makes unlikely that the observed association between MyD88 and 
TIRAP genes and TB is an artifact resulting from incorrect demographic structure of 
the sample. However, the same genes appear to give conflicting results when 
analyzing different populations (Nejentsev, Thye et al. 2008, Miao, Li et al. 2011, 
Sanchez, Lefebvre et al. 2012). Is the irreproducibility of a study necessarily an 
artifact? We think no. New alleles in the human genome are constantly generating a 
wide heterogeneity that is amplified by the interaction between them and with the 
environment. All this genetic heterogeneity is difficult to detect in advance, and 
plausibly contributes to the unreliability of association studies. In addition, throughout 
its long evolutionary history, MTB has developed an effective strategy to make 
difficult own eradication by the host’s immune system: the latency. This represents 
an extra level of difficulty in genetic association study design. On the basis of these 
considerations, the next step was to design a case-control study lacking by the major 
"bias or confounding” factors. The first step was to find an animal model that 
presented the following characteristics: 
 
 Null or minimization environmental factors; 
 Same ethnicity; 
 Discrimination between  population with active and latent TB; 
 A consistent number of cases and controls for acceptable statistical power. 
 
The pulmonary tuberculosis infection can be active (ATI) or latent (LTI), the latter is 
characterized by the presence of dormant bacteria (viable, but not-cultivable on 
normal growth media) (Oliver 2010). The methods commonly used to diagnose latent 
tuberculosis are the tuberculin skin test (TST) or IFN-ɣ assay. However, these 
methods do not distinguish between hosts still infected and those who have 
successfully controlled the infection (Barry, Boshoff et al. 2009). Therefore, MyD88 
and TIRAP genes could influence differently the two forms of infection To define the 
focal point of this research, it was decided to shift on animals from which it should be 
possible to obtain lung biopsies when they were slaughtered. Finally, the 
investigation of bovines was limited to only MyD88 gene for case of force majeure. In 
the population studied, the TIRAP rarer allele has a frequency <0.01 and thus could 
be maintained in the population by recurrent mutations, rather than by natural 
selection. 
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Mycobacterium bovis infection and diagnosis of pulmonary infection 
 
Mycobacterium bovis is the pathogen that causes TB in cattles. In countries where 
programs for the eradication of bovine tuberculosis are efficient (periodic testing for 
farm animals, meat inspection and pasteurization of milk), human tuberculosis due to 
Mycobacterium bovis was reduced to less than 1% of cases, limiting it only people 
with HIV or persons who have prolonged exposure to the infected animals 
(manufacturing people and veterinarians). Mycobacterium bovis has a wide host 
range, which includes numerous wild and breeding species. It is pathogenic for 
humans, while Mycobacterium tuberculosis is not pathogenic in cattle (Ocepek, Pate 
et al. 2005). This feature could be attributed solely to the different gene expression 
between them (Neill, Skuce et al. 2005). Genetic studies have demonstrated the high 
genetic similarity between the two bacterial species (approximately 99.5 % at the 
nucleotide level) (Garnier, Eiglmeier et al. 2003). All of these observations taken 
together provide the biological plausibility of the crucial role played by MyD88 gene 
also against bovine tuberculosis.  
 
Results 
 
Cases and controls diagnosis 
 
The first point was developed an "in-
house assay" able to resuscitate dormant 
mycobacteria. Through the use of protein 
RpfB, which are produced in recombinant 
form in Escherichia coli. It was possible to 
recover dormant mycobacteria from milk 
and lungs from 7 animals treated with 
RpfB, while no colony of bacteria there 
was in the same samples not treated with 
RpfB. The results of the milk and lungs 
were fully concordant. Twenty more 
samples (milk and lungs) were used to 
validate the assay. The test was 
subsequently extended to all animals 
using lung sample collected post-mortem 
(Figure 5-6). A PCR assay was used to 
discriminate between Mycobacterium 
tuberculosis, Mycobacterium bovis or 
Mycobacterium avium (Figure 7). That 
test has determined that all samples analyzed (with ATI or LTI) were infected with 
Mycobacterium bovis. In conclusion, cases with ATI were found positive by PCR and 
bacteriological examination in the absence of RpfB; cases with LTI were found 
positive by PCR and bacteriological examination in the presence of RpfB, but not in 
presence of RpfB, the controls are subjects exposed to Mycobacterium bovis 
(because they come from the same farms where they were taken cases), but PCR 
and the bacteriological test both negative in the presence and absence of RpfB.  
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Experimental design 
 
Also in this case the study was composed of two phases. The first phase involved 
only 50 control animals, which were compared with 50 cases with 50 cases with ATI 
or LTI. Preliminary results showed a significant association of the polymorphic site of 
MyD88 A625C with ATI (P = 0.01, Table 7), but not with LTI (P = 0.84, Table 7). The 
site A625C is located on the intron 1 of the MyD88 gene (Figure 8). This preliminary 
phase of the study has provided two important assumptions: first, that the association 
seems to be quite robust (detected by using only a small number of samples) and, 
second, that the stratification of cases (between the active or latent TB) could provide 
more power to the study. Besides A625C, it was not detected the presence of any of 
the SNPs shown in the reference sequence. To explore the role of A625C, have 
been aligned with 11 different gene sequences of MyD88 belonging to different 
species, in order to study themselves conservation (Figure 9). The low level of 
conservation suggests that the polymorphic site A625C is not under stringent 
selection. Surprisingly, analyzing the sequence of cattle by SCOPE, it was seen 4 
over-represented sequences in the whole bovine genome, which includes the 
polymorphic site A625C (Table 8). That could indicate a possible regulatory role of 
the polymorphism. These data constitute a suitable substrate for further future 
investigations. 
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The heterozygosity at MyD88 and resistance to the active bovine tuberculosis 
 
In the second phase of the study, it was used a larger number of samples: 300 
controls, 150 cases with ATI and 150 cases with, different from those of the first 
phase. Cases with ATI are not in Hardy-Weinberg equilibrium (χ2 = 4.4, Table 7). 
When the test was repeated with the LTI cases, both cases and controls are in 
equilibrium (χ2 controls= 0.9; χ2 cases= 0.3, Table 7). The data suggest an 
association between A625C and ATI, but not between A625C and LTI. First, the most 
stringent Fisher's exact test shows that the heterozygosity (AC status) is strongly 
associated with resistance to ATI (OR 0.19; P= 6.0x10 -12, Table 7), and second, the 
association remains strong even when both homozygous classes are pooled (OR 
0:22; P= 1.8x10-10, Table 7), and thirdly, the site A625C did not affect the 
susceptibility to the LTI (OR 0.83; P= 0:36 and 0:40; Table 7). The binomial logistic 
regression has supported these conclusions (Table 9). 
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The heterozygosis at the MyD88 locus and inflammation 
 
TNF-α, IFN-ɣ and NOS 
profoundly affect 
tuberculosis (Scanga, 
Bafica et al. 2004). It is also 
known that high or low 
levels of inflammation have 
a negative impact on 
tuberculosis (Glickman and 
Jacobs 2001, Doherty and 
Arditi 2004, Fremond, 
Yeremeev et al. 2004). 
Thus, if the heterozygous to 
MyD88 shows an 
intermediate level of 
cytokines than the 
homozygous, the 
association between A625C 
and resistance to the 
Mycobacterium bovis 
acquires a strong biological 
plausibility. To validate this 
hypothesis, we measured 
the mRNA levels of TNF-α, 
IFN-ɣ and NOS in subjects 
with different genotypes 
(AA, AC, CC) and status 
(controls or animals with 
ATI or LTI) (6 classes; 5 
animals/class). The 
expression levels of the 
subjects with ATI or LTI 
were compared with those 
of control subjects with the same genotype. The heterozygous carrier expressed 
levels of TNF-α, IFN-ɣ and NOS significantly lower than those expressed by the AA 
homozygotes. In contrast, the heterozygous show levels only slightly higher than 
those expressed by the homozygous CC, in this case, the difference between them 
did not reach statistical significance (Figure 10). A possible explanation for this is that 
the technique used for the quantification of mRNA levels does not discriminate below 
a determined threshold. Taken together, these data support the conclusion that an 
optimal inflammatory response is associated with the phenotype of A625C. 
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Discussion and Conclusions 
 
The present study has shown that in heterozygous animals at the polymorphic site 
MyD88 have a reduced risk of about 5 times than the ATI (OR 0.19; P= 6.0x10-12, 
Table 7). However, the reduction in risk does not extend to the animals with LTI (OR 
0.83, P= 0:36 and 0:40; Table 7). The heterozygosity at A625C is associated with 
intermediate levels of TNF-α, IFN-ɣ and NOS (Figure 10). Also, the study showed 
differences in the expression of cytokines mRNA between animals of the same 
genotype, but with acute or latent tuberculosis. The difference is particularly evident 
in animals AA (Figure 4). Unfortunately, we cannot attribute these different levels of 
expression at the pathogen or at the host; however, the levels of cytokines are 
potential markers for the reactivation of the disease. The A625C polymorphism, 
which located on the intron 1 of the gene MyD88, adds evidence that non-coding 
regions may affect genes expression. It is not surprising that this happens in the case 
of inflammation, which needs to be subject to a fine and complex regulation. In cattle, 
environmental exposure to the mycobacteria, which occur in the majority of subjects, 
interferes with the diagnosis of TB by TST or IFN- ɣ assay (Hope, Thom et al. 2005). 
The availability of reagents, incubation timing, and the levels of cut-off can affect the 
specificity and sensitivity of these assays (Pai, Riley et al. 2004). The bacteriological 
test post-mortem still remains, to date, the "gold standard" for the diagnosis of this 
infection (Thacker, Harris et al. 2011). Environmental factors (climate, density 
farming, herds’ movements, etc.)  are known as factors that promote tuberculosis 
(Neill, Skuce et al. 2005). Even strong genetic effects on mycobacteria may be 
missed if it does not take into account the environmental effects (Schurr 2007). 
Considerable OR and P value (OR = 0:19; P= 6.0x10-12) reported in this study make 
us cautiously optimistic about the possibility of correctly approaching the genetic 
analysis of this complex disease. The cases were made homogeneous (cases ATI 
and LTI were individually analyzed), the "environmental confounders" were excluded 
(gender and race) or "randomized" (age). More important is that the controls come 
from the same breeding of cases, however, remain infection-free (negative to the 
PCR and bacteriological test) despite having the same probability of becoming 
infected as in the cases. Further, in the present study, we investigated only one race. 
Additionally, the same results from two independent samples of populations offer 
considerably convincing evidence that there has not been stratification. In conclusion, 
the high biological relevance of the gene to study, the careful choice of diagnostic 
criteria, and randomization of environment confounders had been carefully taken into 
great consideration during this journey in the complex field of association studies. 
However, because the association is described for the first time, the results of this 
study are to be considered as preliminary. Finally, the test used here to distinguish 
between latent and active disease could potentially be extended to periodic testing of 
cattle for tuberculosis. The counting of dormant mycobacteria awakened by RpfB in 
milk samples would be an easy way to assess the incidence of latent tuberculosis in 
the population tested, a parameter strongly influenced by the control of the pathogen 
from the host's immune system. 
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Comment 
 
Tuberculosis is influenced by many genes that interact with each other (Chang, 
Linderman et al. 2008) and the environment (Schurr 2007) . The presence of 
mycobacteria is necessary, but not sufficient to acquire the disease (Diamond 1987). 
Often, the stratification of the population is considered as responsible for the false-
positive results obtained from association studies, but rarely has been proven to be 
guilty (Risch 2000, Colhoun, McKeigue et al. 2003). Human studies have shown that 
the stratification could arise when different ethnic groups are mixed (Healy 2006). 
The genetic association studies are characterized by a high rate of false-positive 
results (Risch 2000). This conclusion is often due to the selection of candidate genes 
without a functional relationship with the disease (Lander and Schork 1994, Risch 
2000). In the present studies, MyD88 and TIRAP in the human and MyD88 in bovine, 
have been selected on the basis of a large number of experimental evidences. These 
studies show, at least in the mouse, the importance of gene conserved in the 
"signaling" downstream of the detection of the mycobacterial components and 
induction of immune response (Doherty and Arditi 2004, Fremond, Yeremeev et al. 
2004). In conclusion, these studies have clarified that - as hypothesized – the host’s 
genotype influences strongly the type of infection.  
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Materials and method 
 
Genotyping  
 
DNA was extracted from human blood samples by the phenol-chloroform method 
(Sambrook J, 1989).  The quality of DNA was assessed by run on agarose gel and 
by Nanodrop (ratio 260/280 and 260/230 nm). The PCR was performed using the 
One-Step Real-Time PCR system and the TaqMan universal PCR master mix from 
Applied Biosystems (Life Technologies, Monza, Italy). The PCR program included 
one step at 50 ° C for 2 min, one at 95 ° C for 10 min and 40 cycles at 92 ° C for 15 s 
and 60 ° C for 1 min. The probes used for the gene MyD88 are: rs2585635, 
rs41285117, rs2200055, rs6853, rs7744; for gene TIRAP: rs646005, rs8177352, 
rs625413, rs614700, rs8177374. 
 
Measurement of levels of TNF-α and IFN-ɣ by ELISA 
 
Cytokine levels were determined before the blood donors were genotyped. 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood on 
Ficoll-Hypaque gradient (Sigma, Milan, Italy), centrifuged (400g, 30 min), washed 
with RPMI 1640, distributed (105 PBMCs per well) on a 96-well plate (Falcon, Milan, 
Italy) and incubated with heat-killed Mycobacterium tuberculosis strain H37/Rv (106 
CFU per well) for 48 hours ( the optimal number of Mycobacterium tuberculosis to be 
used in the assay was set by a preliminary dose-response experiments). The 
supernatant was centrifuged (2000g, for 5 min ) and added (50 µl per well) in a 96-
well plate previously coated with mouse anti-human TNF-α- mouse or anti-human - 
IFN-ɣ (BDPharmingen, Milan, Italy; 50 µl diluted to 2x103 per well, incubated for 4h) 
and quenched with 3% BSA (100 µl per well, 2h). Following incubation of the 
supernatant for 4h, the plate was washed with PBS and incubated with: mouse anti-
human TNF-α or mouse anti-human-IFN-ɣ 50 µl diluted 2x103 per well; 4h); 
subsequently it was used rat-anti mouse bounding the peroxidase diluted 103 (50 µl 
per well, 2h) and TMB peroxidase substrate ( 100 µl per well; Biorad, Milan, Italy). 
The optical density was measured at 405 nm. The samples were performed in 
triplicate. 
 
Nitric oxide quantification 
 
The PBMCs were incubated with heat-killed Mycobacterium tuberculosis strain 
H37/Rv (106 CFU per well) for 48 hours, centrifuged and the supernatant (100 µL) 
was mixed with 100 µl of Griess reagent (10 min at Room Temperature). The optical 
density was measured at 570 nm. The concentration of nitrite was measured using 
as a standard of 1, 10, 25 and 50 µM of a solution of sodium nitrite. 
 
Bioinformatics and statistical analysis 
 
OR and 95% confidence intervals were calculated with the Fisher's exact test using 
the statistical package GraphPad Prism version 5 (GraphPad). Sample Size was 
calculated with the module OpenEpi 3.03.17 and the Hardy- Weinberg equilibrium 
was calculated using the Hardy-Weinberg equilibrium calculator 
(http://www.oege.org/software/HWE-mr-calc.shtml). The Mantel-Haenszel test, 
logistic regression analysis coupled with resampling (2000 samples and 99% 
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confidence intervals), the generalized linear model (Garrett, Madden et al. 2004) and 
ANOVA with HSD test of Tuckey's post hoc analysis were performed using the 
statistical package SPSS version 19  MyD88 and TIRAP orthologs were retrieved by 
BLAST analysis (blast.ncbi.nlm.nih.gov/). Alignments were performed with the 
software MAFFT v7.045b (http://mafft.cbrc.jp/allineamento/software) and maps CLC 
Main Workbench 6.8.2 software. Mutations in the TIRAP and protein function was 
predicted by SIFT (http://sift.jcvi.org/) (Kumar, Henikoff et al. 2009) and I-TASSER 
tools (http://zhanglab.ccmb.med .umich.edu/I- TASSER) (Roy, Kucukural et al. 
2010). The human sequence 3'UTR of MyD88 gene was scanned for the 
identification of regulatory elements using the Encyclopedia of DNA Elements 
(ENCODE; http://encodeproject.org/ENCODE/). 
 
Diagnosis of pulmonary infection of bovine 
 
The samples were collected post-mortem in accordance with the guidelines set out 
by the European Food Safety Authority (Serratosa, Arbelot et al. 2004). A portion of 
the infected tissue and afferent lymph node were removed from animals which 
showed macroscopic lung lesions. In the case of animals without visible lesions were 
collected mediastinal, bronchial and retropharyngeal lymph node. Samples from each 
animal consisted of 1 gr or more of tissue. To distinguish between subjects with 
active pulmonary tuberculosis (ATI) and latent pulmonary tuberculosis (LTI), were 
made serial dilutions ( 10-1 to 10-8) of individual lung homogenates in sterile PBS and 
plated (10 µL/ spot; 5 spots/dilution) on agar-Middlebrook (MB) and incubated at 37 ° 
C for 4 to 5 weeks. At the end of the incubation period were counted colonies forming 
units (CFU). Negative samples were further incubated for 10 days in liquid medium 
(MB) supplemented with mycobacterial resuscitation-promoting factor B (RpfB) (5 gr/ 
mL) (Ruggiero, Tizzano et al. 2007) and then counted the CFU. The optimal 
concentration of RpfB used in the test was obtained through preliminary experiments. 
The growth of colonies in the absence of RpfB was indicative of ATI, and colony 
growth only in the presence of RpfB was indicative of LTI. The controls were negative 
for both tests (Figure 6). 
 
The identification of mycobacterial species by PCR analysis. 
 
A colony of Mycobacterium bovis was resuspended in 200 µl of distilled H2O 
containing lysozyme (20 mg/ml, Sigma-Aldrich, St. Louis, MO) and incubated at 37 
°C for 2h. After the incubation time, the DNA was isolated using a DNeasy-kit of 
Qiagen (Hilden, Germany). The PCR was performed as previously described 
(Bakshi, Shah et al. 2005) (Figure 7). 
 
Cases and Controls 
 
The animals included in the study, both cases and controls, come from three herds 
declared to be infected. sex and age as potential confounders, the animals were all 
lactating cows between 40 and 90 months of age. This age interval was selected to 
represent subjects matched for age (as much as it was realistic) and, at the same 
time, a population sample sufficiently numerous to provide adequate power to the 
study. The average ages of the cases and controls were 65.4±5.2 and 69.6±3.9 
months, respectively. To curb stratification, both cases and controls were from the 
same herds and the same breed (Friesian); to keep cases and controls genetically 
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unrelated to each other, when mother and daughter were present, one of the two was 
excluded. 
 
MyD88 genotyping 
 
The intron/exon boundaries of the bovine MyD88 gene were established by matching 
the published mRNA sequence of the bovine MyD88 gene (GenBank accession 
number NM_001014382.2) and the DNA sequence of the human MyD88 gene 
(GenBank accession number NC_000003.11). Alignment was carried out using 
DNAsis software (Hitachi Solutions America, San Francisco, CA). DNA was extracted 
from lung specimens with a QIAamp DNA kit (Qiagen, Hilden, Germany). The 
primers were 5’-TGAAGGAGTACCCCGCGC-3’ (forward) and 5’-
GATGCCTGCCATGTCATT-3’ (reverse). Conditions of the PCR were 7 min at 97°C 
and then 45 s at 94°C, 30 s at 60°C, and 1.5 min at 72°C (35 cycles), with a final 
extension for 5 min at 72°C. The 1,210-bp fragments from 20 cases and 20 controls 
were sequenced using an ABI 3730 DNA analyzer (Applied Biosystems, Foster City, 
CA) and aligned by use of Chromas software (Technelysium, Queensland, Australia). 
The sequences were used to design primers and TaqMan probes targeting 
specifically the single nucleotide polymorphism (SNP) located 625 bp downstream of 
exon 1 (A625C). The forward and reverse unlabeled primers were 5’-
GGTGGCGTGGTACTTTGC-3’ and 5’-TTTCTCCTCTACGGGCTGTCT-3=, 
respectively. The TaqMan VIC- and 6-carboxyfluorescein-labeled probes were 5’-
TAGCAAGGGAGACATT-3’ and 5’-TAGCAAGGGCGACATT-3’, respectively, where 
the underlining and boldface indicate the polymorphic nucleotide. PCR conditions 
were 30 s at 60°C, 10 min at 95°C, and then 40 cycles each lasting 15 s at 95°C and 
1 min at 60°C. Genotyping was carried out with the investigator blinded to the case or 
control status of the animals being tested. 
 
TaqMan gene expression assay 
 
TNF-α, IFN-ɣ, and NOS2 mRNA levels in the lung specimens were measured using 
the TaqMan gene expression assay and a StepOne instrument (Applied Biosystems, 
Foster City, CA). Total RNA (2µg) from mediastinal, bronchial or retropharyngeal 
lymph node was reverse transcribed using a High Capacity cDNA reverse 
transcription kit (Applied Biosystems, Foster City, CA). The real-time quantitative 
PCRs were carried out following the manufacturer’s protocol. The identification 
numbers of the probes are Bt03259155_g1 (TNF-α bovine), Bt03212722_g1 (IFN-ɣ), 
Bt03249602_g1 (NOS2), and Bt03279175_g1 (α-actin). Five animals for each 
genotype (AA, AC, CC) and class (control, active and latent tuberculosis) were tested 
in triplicate. Relative sample quantification was carried out by the comparative 2-ΔΔCT 
method (where CT represents the threshold cycle). The endogenous control gene 
was α-actin. The amplification efficiency of target (TNF-α, IFN-ɣ, and NOS) and 
reference (α-actin) genes was approximately the same (slope <0.1). 
 
Sample size calculation 
 
The data for 50 cases with active tuberculosis and 50 controls (odds ratio [OR], 0.3; 
proportion of controls with susceptible genotype, 0.46) showed that a sample of 127 
cases and 127 controls would provide 96% power and a two-sided significance level 
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of 0.01. The study enrolled 150 animals with acute tuberculosis, 150 animals with 
latent tuberculosis, and 300 controls. 
 
Other methods 
 
Logistic regression 
 
The binomial logistic regression analysis is used in epidemiology to predict the 
outcome (variable dependent) on the basis of a set of descriptive variables 
(independents), both qualitative and quantitative. The dependent variable is 
measured with value of “yes” or “no” (dichotomy variable) and describes the outcome 
occurring of random event. Logistic model estimates the logit transformation of 
probability of an event occurring (disease) on the basis of other variables (e.g. age, 
gender, SNP etc.). The output of logistic regression is confined to values between 0 
and 1and hence it is interpreted as probability: 
 
Logit (P) = ln ( ) = α+β1X1 + β2X2 + βnXn 
 
Where P= Probability of condition of interest (disease). α is the intercept; Coefficient 
β (and its standard errors and significance level) estimates how quickly the 
probability changes with changing X a single unit; X represents independent 
variables along with other covariates, e is the base of the natural logarithm (about 
2.718). The logit transformation works as a link function between the probability and 
the linear regression expression. Fisher’s exact test and analysis of variance with the 
Tukey post hoc test were performed with GraphPad Prism software, version 5. Binary 
logistic regression was performed with the SPSS statistical package, version 18. 
Hardy-Weinberg equilibrium and relative risk reduction were calculated as described 
previously (Modiano, Luoni et al. 2001). Conservation analysis was carried out on 11 
MyD88 genomic sequences retrieved from the Nucleotide BLAST database (blast-
.ncbi.nlm.nih.gov/). The alignment was performed using the T-COFFEE multiple-
sequence alignment server (tcoffee.crg.cat/) and map visualized with CLC Main 
Workbench software, version 6.8.2. The bovine intron 1 sequence was scanned for 
identification of overrepresented motifs by using the SCOPE (Suite for Computational 
identification of Promoter Elements) motif finder (http://genie.dartmouth.edu/scope/). 
Regulatory elements were searched for using the Encyclopedia of DNA Elements 
(ENCODE; http://encodeproject.org/ENCODE/). 
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ORIGINAL ARTICLE
The MyD88 rs6853 and TIRAP rs8177374 polymorphic sites
are associated with resistance to human pulmonary tuberculosis
R Capparelli, F De Chiara, A Di Matteo, C Medaglia and D Iannelli
Toll-like receptors recognize several components of Mycobacterium tuberculosis, the main causative agent of tuberculosis. The
signaling pathways leading to activation of the immune response require the MyD88 and TIRAP genes. The hypothesis that
polymorphic variants of these genes inﬂuenced resistance to pulmonary tuberculosis was tested by a case–control study (400 cases
and 400 controls). Heterozygosity at the polymorphic sites MyD88 rs6853 (alleles: A, G) or TIRAP rs8177374 (S180L) (alleles: C, T) is
associated with resistance to pulmonary tuberculosis (P: 7.8 10 8 and 2 10 6, respectively). Double heterozygosity confers
higher protection levels (P: 10 14 to 2 10 16). The logistic regression model displayed that the double homozygous genotype
GG/TT predisposes to the disease (odds ratio (OR): 5.78) and the AG/TT genotype combination neutralizes the protective activity
exerted by AG (OR: 3.05). The same model showed that the risk of developing the disease increases with age from 31–40 years to
71–80 years (OR: 1.32–13.59).
Genes and Immunity advance online publication, 26 September 2013; doi:10.1038/gene.2013.48
Keywords: MyD88; TIRAP; Mycobacterium tuberculosis; gene interaction
INTRODUCTION
Toll-like receptors (TLRs) are pattern recognition receptors (PRR),
which sense invading pathogens by recognizing pathogen-
associated molecular patterns (PAMPS). TLRs recognize several
PAMPS of the Mycobacterium tuberculosis, such as the 19 kD
lipoprotein (19LP), soluble tuberculosis factor (STF), lipomannan
(LM), lipoarabinomannan (LAM) and the heat shock protein 65
(HSP65). In the presence of adapter proteins, PAMPs recognition
initiates signaling pathways that lead to activation of the factor NF-
kB and induction of a rapid immune response, innate and adaptive.
Sensing of the mycobacterial DNA requires TLR-9 and the adapter
protein myeloid differentiation factor 88 (MyD88); 19LP, LM, LAM
and STF require TLR-2 and MyD88, whereas the HSP65 requires TLR-
4, MyD88 and the TIR domain-containing adapter protein (TIRAP;
also known as Mal).1 The MyD88 and TIRAP genes map to
chromosomes 3p21.3-p22 and 11q24.2,3 respectively. MyD88-
deﬁcient mice (MyD88 / ) display defective production of
TNF-a, IL-12 and NO, and upon infection with M. tuberculosis die
within 4 weeks.4 TIRAP / mice instead can efﬁciently control
M. tuberculosis infection.5 The TIRAP single-nucleotide polymorphism
C558T is associated with susceptibility to meningeal tuberculosis6,7
and the single-nucleotide polymorphism S180L (rs8177374) of the
same gene with protection against malaria, tuberculosis,
bacteremia and invasive pneumococcal disease.3 Subsequent
studies however did not conﬁrm the protective role of S180L
against tuberculosis.8,9 One more study10 reported that neither
TIRAP (rs352165 and rs352167) nor MyD88 (rs4988457 and
rs6767684) genes inﬂuence tuberculosis. The discrepancies that
emerged when these genes—or even the same single-nucleotide
polymorphism (rs81777374)3,9—were studied in different
ethnicities intrigued the present authors, who decided to
investigate the association of MyD88 and TIRAP with pulmonary
tuberculosis in a sample of Italian population. Here they show that
in this population heterozygosity at the polymorphic sites MyD88
rs6853 or TIRAP rs81777374 is associated with resistance to
pulmonary tuberculosis. The two genes cooperate or antagonize
each other, depending upon the allelic combination.
RESULTS
Study design
To reduce the type I error and the drawback of multiple
comparison corrections, a two-stage study was followed. The ﬁrst
stage was limited to 100 cases and 100 controls and it included the
polymorphic sites TIRAP rs8177374 and MyD88 rs6853. The
rs8177374 site was included because in previous studies it yielded
contrasting results;3,9 the rs6853 site was included because it was
the only one, among the ﬁve tested, to display a frequency of the
rarer allele 40.05. Both polymorphic sites displayed a statistically
signiﬁcant association with the disease (P-value o0.05) (Table 1).
Based on the data from this preliminary study (MyD88: odds ratio
(OR): 0.40 and proportion of controls with susceptible genotypes:
0.61; TIRAP: OR: 0.48 and proportion of controls with susceptible
genotypes: 0.64), it was calculated that a sample of 185 cases and
185 controls (in the case of MyD88) and 313 cases and 313 controls
(in the case of TIRAP) would provide 96% power and a two-sided
signiﬁcance level of 0.01. The second stage of the study was
conducted on 400 cases and 400 controls (independent from cases
and controls included in the preliminary test). To limit the study to
a homogeneous disease spectrum, cases were all patients with a
clinical diagnosis of pulmonary tuberculosis, conﬁrmed by chest
X-ray, bacteriological and PCR-positive tests. The bacteriological
test was carried out on sputum samples. Cases were all treated
at the Monaldi hospital (Naples), the southern Italy reference
center for tuberculosis. Controls were household contacts (spouses
or husbands of patients) without clinical signs of tuberculosis
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(negative to the interferon test). Thus, controls were genetically
unrelated subjects, who remained healthy though exposed (42
years) to the pathogen. Criteria for deﬁnition of cases and controls
were the same for both stages of the study. Cases and controls
were collected over a 5-year time period. In this time interval six
controls became positive to the interferon test and were excluded.
Cases consisted of 258 males and 142 females (mean age: 50±19
years); controls consisted of 222 males and 178 females (mean age:
49±17 years). The study was approved by the ethic committee of
the Monaldi hospital. Informed consent was obtained from all
subjects who participated to the study.
Heterozygosity is associated with protection against pulmonary
tuberculosis
Genotype frequencies at the rs6853 and rs8177374 markers were
in Hardy–Weinberg equilibrium among controls but not among
cases (Table 2), as expected if the single-nucleotide polymorph-
isms and pulmonary tuberculosis were associated. The association
was conﬁrmed by Fisher’s exact test (Table 2). At both loci,
heterozygosity (the AG or CT status) was associated with
protection from pulmonary tuberculosis; protection persisted
when the two classes of homozygotes were pooled (AG vs
AAþ GG or TC vs TTþ CC) (Table 2).
Age is a known risk factor for pulmonary tuberculosis.11
Therefore, ORs associated with different genotypes were
corrected from the age confounding effect by the Mantel-
Haenszel test (Table 3). After correction, double heterozygosity
(AG/CT) still afforded a higher level of protection (OR: 0.16)
compared with single heterozygosity (AG, OR: 0.41; CT, OR: 0.42)
(Table 3). To know how the age risk varied across strata, the data
were then re-analyzed according to the logistic regression model.
The analysis was restricted to the numerically more representative
Table 1. Association of the MyD88 rs6853 and TIRAP rs8177374 polymorphic sites with pulmonary tuberculosis. Exploratory study in an Italian
population sample
Genes Status Number of individuals in each genotype Total HWE (P) Allelic frequency OR (95% CI)a P-valuea
Co Ra
AA AG GG AG vs (AAþGG)
MyD88 Cases 73 21 6 100 0.017 0.84 0.16 0.40 (0.22–0.77) 0.008
Control 48 39 13 100 0.267 0.68 0.32
CC CT TT CT vs (CCþ TT)
TIRAP Cases 76 22 5 103 0.058 0.84 0.16 0.48 (0.25–0.90) 0.029
Control 60 36 4 100 0.624 0.78 0.22
Abbreviations: Co, common allele (MyD88: A; TIRAP: C); Ra, rare allele (MyD88: G; TIRAP: T). aCI (confidence intervals) and P-values were calculated with the
Fisher’s exact test.
Table 2. Association of the MyD88 rs6853 and TIRAP rs8177374 polymorphic sites with pulmonary tuberculosis
Genes Status Number of
individuals in
each genotype
Total HWE (P) Allelic
frequency
OR (95% CI)a OR (95% CI)a P-valuea
Co Ra
Italian AA AG GG AG vs AA AG vs AAþGG
MyD88 Cases 297 89 14 400 0.029 0.85 0.15 0.40 (0.28–0.55) 5.8 10 9 0.42 (0.31–0.59) 7.8 10 8
Control 213 160 27 400 0.68 0.73 0.27
CC CT TT CT vs CC CT vs CCþ TT
TIRAP Cases 318 71 11 400 0.006 0.88 0.12 0.44 (0.31–0.62) 1.2 10 6 0.44 (0.31–0.63) 2 10 6
Control 258 130 12 400 0.36 0.81 0.19
Romanian AA AG GG AG vs AA AG vs AAþGG
MyD88 Cases 104 34 12 150 8 10 4 0.81 0.19 0.44 (0.26–0.74) 0.003 0.47 (0.28–0.79) 0.005
Control 78 57 15 150 0.34 0.71 0.29
CC CT TT CT vs CC CT vs CCþ TT
TIRAP Cases 100 40 10 150 0.04 0.8 0.2 0.55 (0.33–0.90) 0.01 0.53 (0.32–0.86) 0.01
Control 84 61 5 150 0.12 0.76 0.24
Ukrainian AA AG GG AG vs AA AG vs AAþGG
MyD88 Cases 117 27 6 150 0.01 0.87 0.13 0.45 (0.26–0.78) 0.004 0.48 (0.28–0.82) 0.01
Control 92 47 11 150 0.16 0.77 0.11
CC CT TT CT vs CC CT vs CCþ TT
TIRAP Cases 119 26 5 150 0.03 0.88 0.12 0.41(0.24–0.71) 0.002 0.42 (0.24–0.71) 0.002
Control 95 50 5 150 0.61 0.8 0.2
All ethnicities AA AG GG AG vs AA AG vs AAþGG
MyD88 Cases 518 150 32 700 5 10 6 0.85 0.15 0.42 (0.32–0.53) 8 10 13 0.45 (0.35–0.57) 3 10 11
Control 383 264 53 700 0.42 0.74 0.26
CC CT TT CT vs CC CT vs CCþ TT
TIRAP Cases 537 137 26 700 1.8 10 5 0.87 0.13 0.46 (0.35–0.59) 5.3 10 10 0.46 (0.36–0.69) 4.6 10 10
Control 437 241 22 700 0.10 0.80 0.20
Abbreviations: Co, common allele (MyD88: A; TIRAP: C); Ra, rare allele (MyD88: G; TIRAP: T). aCI (confidence intervals) and P-values were calculated with the
Fisher’s exact test.
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age categories, consisting of X45 subjects. Apart from the
category 31–40 years vs 21–30 years (apparently protected,
P¼ 0.31), the model showed that the risk of developing the
disease increases with age from the 31–40 years to the 71–80
years categories, as shown by the steadily increasing ORs (from
1.32 to 13.59) (Table 4). Clearly, aging—and possibly aging-
associated covariates (smoking, diabetes and prolonged exposure
to the pathogen)—can overcome genetic resistance. The authors
did not have complete access to the clinical records of the
patients and therefore could not investigate the role of these
potential confounders.
The logistic regression model was also used to dissect the
contribution of single genotypes and their interactions with the
ORs. Particularly evident is the interaction between the AG and CT
genotypes (estimated OR: 0.09) and in the opposite direction the
interactions between the GG and TT, AA and CC, and AA and CT
genotypes (OR: 5.78, 5.78, 7.46) (Table 5).
The association resists stratiﬁcation
The study was extended to one sample of people from Romany
and one from Ukraine. The study, though underpowered,
conﬁrmed the protective role of the heterozygous status at the
rs6853 (P¼ 0.003–0.004) and rs8177374 (P¼ 0.01–0.02) sites
(Table 2). The protective role persisted when the samples from
Romany, Ukraine and Italy were pooled (rs6853: P¼ 8 10 13;
rs8177374: P¼ 5.3 10 10) (Table 2). Thus, the association of
rs6853 and rs8177374 with pulmonary tuberculosis extended to
the several ethnicities tested in this study and resisted the artiﬁcial
stratiﬁcation determined by pooling different ethnicities.
Heterozygosity curbs inﬂammation
Peripheral blood mononuclear cells (PBMCs) from healthy
volunteers (nine genotypic groups; ﬁve samples/group) were
stimulated with heat-killed M. tuberculosis strain H37Rv and the
levels of TNF-a, IFN-g and NO were then measured. In the AA
genotype context, CT subjects displayed intermediate levels of
TNF-a, IFN-g and NO compared with CC or TT subjects. In the AG
genotype context, the data showed the same tendency, though
the differences between subgroups were not always signiﬁcant.
Further, the lowest cytokines levels were observed in the subjects
carrying the GG genotype, as if the A allele favors cytokines
production, whereas the G allele curbs it. On the whole, the data
indicate that heterozygosity is associated with an intermediate
level of cytokines and NO (Figure 1).
The experimental data were then analyzed by the generalized
linear model. This methodology permits to study relationships
between response variables (in the present study IFN-g, TNF-a or
NO) and a set of predictor variables (in the present study MyD88
and TIRAP) to extract patterns. In addition, the methodology can be
applied to data that presumably are not normally distributed (as in
the present case, where only a small number of blood samples was
examined). The model calculated the parameters b1, b2 and b3,
which measure how MyD88, TIRAP and the MyD88–TIRAP
interactions inﬂuence the levels of IFN-g, TNF-a and NO. Phrased
another way, the model quantiﬁed the relationship between
predictor variables and their interactions with one response
variable (the effect of the MyD88 or TIRAP genotypes on each
Table 3. Age confounding effect assessed by weighted Mantel–Haenszel test
MyD88 TIRAP MyD88/TIRAP
AA AG GG CC CT TT AA/CC AA/CT AA/
TT
AG/
CC
AG/CT AG/
TT
GG/
CC
GG/
CT
GG/
TT
OR 2.65 0.41 2.27 0.42 1.99 2.12 0.16
CI (1.9–3.6) (0.3–0.6) n.s. (1.6–3.2) (0.3–0.6) n.s. (1.5–2.7) (1.7–3.6) n.s. n.s. (0.1–0.3) n.s. n.s. n.s. n.s.
P 2.8 10 10 1.8 10 8 7.6 10 7 6.5 10 7 3.2 10 6 5.5 10 3 1.3 10 12
Abbreviations: CI, 95% confidence interval; OR, odds ratio; P, significance level; n.s., non significant.
Table 4. Influence of age on pulmonary tuberculosis assessed by the
logistic regression model procedure, which includes 2000 bootstrap
re-sampling
Regression term OR P-value
Age class
31–40 vs 21–30 0.31 5.0 10 4
41–50 vs 31–40 1.32 0.29
51–60 vs 41–50 8.71 5.0 10 4
61–70 vs 51–60 13.59a 5.0 10 4
71–80 vs 61–70 1.38 0.27
Constant 0.63 2.0 10 3
Abbreviation: OR, odds ratio estimated by the logistic regression model.
aExample of OR calculation. OR of people aged 65 years compared with
people belonging to the 51–60 years category is 13.59 (61–70 vs 51–60).
Table 5. Influence of the MyD88 and TIRAP genotypes on pulmonary
tuberculosis assessed by the logistic regression model procedure,
which includes 2000 bootstrap re-samplings
Regression term ORa P-value
MyD88
MyD88 (AG vs AA) 0.50 0.01
MyD88 (AG vs GG) 0.64 0.09
MyD88 (GG vs AA) 0.78 0.41
TIRAP
TIRAP (CT vs CC) 0.58 0.03
TIRAP (CT vs TT) 0.80 0.45
TIRAP (TT vs CC) 0.73 0.29
Effects between loci
MyD88(AG) by TIRAP(CT)b 0.09 5.0 10 4
MyD88(AG) by TIRAP(TT)b 3.05 0.13
MyD88(GG) by TIRAP(CT)b 0.77 0.71
MyD88(GG) by TIRAP(TT)c 5.78 0.02
MyD88(AA) by TIRAP(CC)c 5.78 0.03
MyD88(AA) by TIRAP(CT)c 7.46 1.5 10 3
MyD88(AG) by TIRAP(CC)c 1.90 0.34
Constant 0.63 2.0 10 3
Abbreviations: OR, odds ratio estimated by the logistic regression model;
vs, within locus comparisons; by, between loci interactions; /, reference
genotype (note C) is double heterozygous. aDouble heterozygotes (AG/
CT), compared with double homozygotes (AA/CC) have the OR: 0.5 (AG vs
AA) x 0.58 (CT vs CC) x 0.09 (AG by CT)¼ 0.026. bThe reference genotype is
MyD88(AA)/TIRAP(CC). cThe reference genotype is MyD88(GG)/TIRAP(TT).
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cytokine). The model predicted the levels of the cytokines and NO
of volunteers on the basis of their genotypes at the MyD88 and
TIRAP loci, with surprising accuracy (Table 6). The predictive power
of the model collapsed when the two loci were analyzed separately.
This ﬁnding suggests that the two loci strongly cooperate to
control the disease. This conclusion is strongly supported by the
evidence that TIRAP and MyD88 form heterodimers.12
In silico analysis of polymorphic sites
The site rs6853 resides in the 30UTR region of the MyD88 gene.
Comparison of genomic sequences from different species showed
that both the A and G nucleotides are conserved across species,
suggesting that they are maintained—or at least tolerated—by
natural selection (Figure 2). Further, the rs6853 was found to
overlap with 4 ENCODE tracks (H3K4Me1, H3K4Me3, H3K27Ac and
Broad Chromatin HMM marks) detected by Chromatin Immuno
Precipitation Sequencing (ChIP-Seq) technique. This ﬁnding points
out the potential of the rs6853 polymorphic site—though it is
located in the 30UTR—to inﬂuence the interaction of the MyD88
mRNA with protein factors.
The site rs8177374, residing on the exon 5 of the TIRAP gene,
provided the opportunity to test whether the change of a serine
to leucine at position 180 alters the protein structure. The amino
acids were both frequently represented at position 180 among the
TIRAP proteins from 22 mammalian species and the SIFT algorithm
predicted that they both are compatible with protein activity
(Figure 3). At the same time, the I-TASSER server predicted that the
amino-acid change (S to L) at position 180 affects the secondary
and tertiary structures of the TIRAP protein. This ﬁnding extends to
the A and B isoforms originating from the same mRNA molecule
by alternative splicing (Figure 4) and provides further ground to
the biological plausibility of the polymorphism.
DISCUSSION
Very little is known about the crosstalk occurring among genes
inﬂuencing pathogen resistance. In this article we explored how
the genes MyD88 and TIRAP inﬂuence each other. The hypothesis
that the two genes might interact seemed plausible, as the MyD88
and TIRAP proteins both act as signaling molecules of the TLRs.1
We found that the two genes cooperate or antagonize each other,
depending upon the allele combination. Heterozygosity at both
loci provides stronger protection (P¼ 1.3 10 12, age-corrected;
Table 3) than heterozygosity at one single locus (P(MyD88)¼ 7.8
 10 8; P(TIRAP)¼ 2 10 6, Table 2). At the same time, in AG/TT
subjects the genotype TT neutralizes the protection afforded by
the genotype AG (Table 5). These data, though limited, clearly
show how the concurrent analysis of two or more genes working
along the same pathway helps to better deﬁne the phenotype
(show how independent genes may contribute to shape the
same phenotype). The approach therefore can help to design
case–control studies that are clinically more relevant (studies more
likely to predict disease outcome). The evidence that the gene
under study can be inﬂuenced by background genes can also
contribute to explain why the same gene might be associated
with protection to a pathogen in one population but not in
another one.
In general, subjects heterozygous at the MyD88 or the TIRAP
loci display intermediate levels of IFN-g, TNF-a or NO (Figure 1).
IFN-g, TNF-a and NO have a major role against M. tuberculosis
infection.13–16 NO exerts strong anti-mycobacterial activity and,
along with TNF-a, favors granuloma formation.17 IFN-g induces
the production of NO,16 expression of MHC II molecules and
antigen presentation.15 However, there is also evidence that
overexpression of these molecules favors tuberculosis. Many of
the symptoms of tuberculosis are caused by the immune response
of the host, rather than by the mycobacterium.18 Disease
reactivation has been observed after therapeutic treatment with
TNF-a19 or in HIV-infected patients after antiretroviral therapy.20
As deﬁciency as well as overexpression of TNF-a, IFN-g or NO favor
tuberculosis, the biological advantage of an intermediate level of
pro-inﬂammatory cytokines and NO production becomes clear.
This biological advantage is more manifest in the double
heterozygotes (Table 5), showing that the crosstalk between
MyD88 and TIRAP extends from the epidemiological level to the
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Figure 1. Effect of heterozygosity at the TIRAP or MyD88 loci on levels of TNF-a, IFN-g and NO. The differences in cytokines and NO levels
between the AA, GG and AG genotype subgroups were assessed by the ANOVA with Tukey’s post hoc test coupled with bootstrap re-sampling
(2000 samples and CI 99%). The asterisk indicates statistically significant differences (Po0.001).
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molecular level (Figure 1). The advantage expressed by hetero-
zygotes suggests that allelic frequencies at the rs6853 and
rs8177374 polymorphic sites are maintained by balanced poly-
morphism, where homozygosity is associated with pulmonary
tuberculosis and heterozygosity with resistance. The hypothesis of
the balanced polymorphism agrees with the evidence that
nucleotides (AG and CT) at the rs6853 and rs8177374 sites
respectively are highly conserved throughout speciation (Figures 2
and 3). As the TIRAP gene confers resistance to several diseases,3
allelic frequencies at this locus might reﬂect multiple selective
Table 6. Effects of the MyD88 and TIRAP genotypes on IFN-g, TNF-a and NO levels estimated by the Generalized Linear Model procedure
Genotype
predictors
[IFN-g](pgml) [TNF-a](pgml) [NO](pgml)
Parameter
(b)
P-value Predicted
mean
Observed
meana
Parameter
(b)
P-value Predicted
mean
Observed
meana
Parameter
(b)
P-value Predicted
mean
Observed
meana
Constant (k) 6.55 1.00 10 89 nab 7.51 1.00 10 99 na 1.07 1.00 10 82 na
MyD88 (b1)
c
AA 0.95 1.00 10 78 na 248.22 (a)  0.07 9.43 10 2 na 363.22 (a)  0.29 4.16 10 7 na 5.34 (a)
AG 0.85 1.00 10 99 na 206.01 (b) 0.28 3.92 10 11 na 258.92 (b) 0.30 3.13 10 7 na 3.78 (b)
GG 0.00 na 112.29 (c) 0.00 na 172.33 (c) 0.00 na 1.83 (c)
TIRAP (b2)
c
CC 0.23 3.69 10 87 na 203.06 (a)  0.25 3.21 10 12 na 306.80 (a)  0.31 1.00 10 94 na 4.49 (a)
CT 0.61 1.00 10 69 na 208.45 (a) 0.10 1.70 10 2 na 274.80 (b)  0.32 4.57 10 8 na 3.88 (b)
TT 0.00 na 140.52 (b) 0.00 na 190.61 (c) 0.00 na 2.13 (c)
Effect between loci (b3)
c
AA by CC 0.40 2.30 10 15 280.14 283.33 (a) 1.63 1.00 10 77 451.94 453.08 (a) 2.39 1.00 10 93 7.26 7.24 (a)
AA by CT  0.18 1.73 10 3 243.88 245.55 (b) 0.99 1.00 10 85 369.65 370.00 (b) 1.93 1.00 10 99 5.24 5.23 (b)
AA by TT 0.00 181.02 182.00 (c) 0.00 173.65 173.33 (c) 0.00 1.72 1.71 (c, d, e)
AG by CC 0.20 4.12 10 4 227.54 227.50 (b) 0.78 1.00 10 83 319.57 320.50 (d) 1.13 1.00 10 81 4.56 4.57 (f )
AG by CT  0.28 2.93 10 7 212.31 212.23 (d) 0.07 1.92 10 1 249.00 249.53 (e) 0.93 1.00 10 87 3.94 3.94 (g)
AG by TT 0.00 168.90 169.00 (c) 0.00 221.32 220.83 (e, f ) 0.00 2.58 2.59 (h)
GG by CC 0.00 109.90 110.58 (e) 0.00 153.28 153.66 (c) 0.00 1.69 1.70 (c, i, j)
GG by CT 0.00 143.01 143.33 (f ) 0.00 195.36 195.16 (c) 0.00 1.68 1.69 (d, i, k)
GG by TT 0.00 93.70 93.89 (e) 0.00 182.28 182.00 (c, f ) 0.00 2.10 2.10 (e, h, j, k)
Within each dependent variable (IFN-g, TNF-a and NO levels), the b1, b2 and b3 parameters weigh the effect of predictors (MyD88 and TIRAP genotypes) on the
dependent variable fitting the model Y¼ 2kþb1(MyD88)þb2(TIRAP)þb3(MyD88*TIRAP). Abbreviation: na, not applied. aDifferent letters indicate statistically significant
differences between genotypes at Tukey’s HSD post hoc test (Po0.001). bThe model predicts cytokines and NO levels based on the MyD88 and TIRAP
genotypes and their interactions. The model was not accurate when applied to one single genotype. cRedundant parameters are set equal to 0.
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pressures. Finally, the crucial role exerted by TNF-a, IFN-g and NO
on tuberculosis14–19 and the inﬂuence of the MyD88 and TIRAP
genes on the control of these factors (Figure 1) suggest that the
association is between MyD88 and TIRAP, rather than genes
closely linked to them.
Disturbingly, association studies lack reproducibility.21,22 The
following characteristics of the present study invite to a cautious
optimism about its reproducibility: independent replication
(adoption of a two-stage study design, which directly tested
reproducibility of the association); low P-value (10 6–10 8);
selection of homogeneous cases (the study enrolled only
patients with pulmonary tuberculosis, clinically diagnosed and
conﬁrmed by chest X-ray and positive bacteriological and PCR
tests); use of appropriate controls (subjects without the disease,
but exposed to M. tuberculosis and genetically unrelated to cases);
biological plausibility of the genes selected for study1,16 (Figure 1).
Further, the evidence that the association is found in three
independent ethnicities (Table 2) makes it unlikely that it is an
artifact arising from the demographic structure of the sample
population examined.
The association of the MyD88 and TIRAP genes with pulmonary
tuberculosis provided contrasting results when examined in
different populations.3,8–10 Is non-reproducibility necessarily an
artifact? We think not. New alleles constantly arise in the human
genome,23,24 creating a vast genetic heterogeneity, which
interactions between genes and the environment further
amplify. All this genetic heterogeneity is difﬁcult to detect a
priori and plausibly contributes to the irreproducibility of
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Figure 4. Predictive comparative analysis of TIRAP proteins translated from the common and rare alleles polymorphic at the site rs8177374.
Sequences from the common allele (Sequence 1 and 3) and the rare allele (Sequence 2 and 4) are compared based on bi- and tridimensional
models generated by I-TASSER (http://zhanglab.ccmb.med.umich.edu/I-TASSER/), which predicts secondary and tertiary structures.
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association studies. This concept is not new25 and recently has been
proposed again.26 Replication studies are one way for distinguishing
between artifacts and true associations.27,28 One single study may
not be trusted, but two or more concurrent and methodologically
meaningful studies reinforce each other. Metanalysis of 25
association studies indicates that two independent studies both
with Po0.001 have high replication probability.29
In conclusion, the association of rs8177374 with pulmonary
tuberculosis (characterized by P-values o9.6 10 8 in the study
by Khor et al.3 and 2 10 6 in this article; Table 2) very likely will
be conﬁrmed to affect the risk of the disease also in future studies,
possibly as a population-limited risk factor. The rs6853 site
instead—associated with tuberculosis in this study (P¼ 7.8 10
8; Table 2) but not in two previous ones8,10—at present must
stand as an exploratory, hypothesis-testing study.
MATERIALS AND METHODS
Genotyping
DNA was extracted from blood samples with the phenol–chloroform
method.30 PCR was carried out using probes, the step-one real-time PCR
system and the TaqMan universal PCR master mix from Applied Biosystems
(Life Technologies, Monza, Italy). The PCR program included one step at
50 1C for 2min, one at 95 1C for 10min and 40 cycles at 92 1C for 15 s and
60 1C for 1min.
ELISA measurement of IFN-g and TNF-a
Cytokine levels were determined before the blood of donors was
genotyped. PBMCs were separated from whole blood on Ficoll-Hypaque
(Sigma, Milan, Italy), centrifuged (400 g, 30min), washed with RPMI 1640,
distributed (105 PBMC per well) on a 96-well plate (Falcon, Milan, Italy) and
incubated with heat-killed M. tuberculosis strain H37/Rv (106 CFU per well)
for 48 h (the optimal number of M. tuberculosis to use was set in advance
by a dose-response experiment). The supernatant was centrifuged (2000 g
for 5min) and added (50ml per well) to a 96-well plate previously
sensitized with mouse anti human TNF-a or mouse anti human IFN-g (BD-
Pharmingen, Milan, Italy; 50ml diluted 2 10 3 per well; 4 h) and
quenched with 3% BSA (100 ml per well; 2 h). Following incubation of the
supernatant for 4 h, the plate was washed with PBS and incubated (in the
order) with mouse anti-human TNF-a or mouse anti-human IFN-g diluted
2 10 3 (50ml per well; 4 h), rat anti mouse labeled with horse radish
peroxidase diluted 10 3 (50ml per well; 2 h) and TMB peroxidase substrate
(100ml per well; Biorad, Milan, Italy). Optical density was measured at
405 nm. Samples were run in triplicate.
Measurement of NO
Following incubation with M. tuberculosis, the PBMCs were centrifuged and
the supernatant (100ml) was mixed with 100ml of Griess reagent (10min).
Optical density was measured at 570 nm. Nitrite concentration was
measured using as standards 1, 10, 25 and 50 mM sodium nitrite solutions.
Statistical analysis and bioinformatics
ORs and 95% conﬁdence intervals were calculated by Fisher’s exact test
using the statistical package GraphPad Prism version 5 (GraphPad, La Jolla,
CA, USA). Sample size was calculated with the OpenEpi module 3.03.17 and
the Hardy–Weinberg equilibrium by the Hardy–Weinberg calculator
(http://www.oege.org/software/hwe-mr-calc.shtml). The Mantel–Haenszel
test, the binary logistic regression analysis coupled with bootstrap re-
sampling (2000 samples and 99% conﬁdence intervals), the Generalized
Linear Model procedure31 and the univariate ANOVA with Tucky’s HSD post
hoc test were carried out using the statistical package SPSS version 19 (IBM
Corporation, Armonk, NY, USA). MyD88 and TIRAP orthologs were retrieved
by BLAST analysis (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Alignments were
carried out with MAFFT software v7.045b (http://mafft.cbrc.jp/alignment/
software) and maps visualized with the CLC Main Workbench 6.8.2
software. The relevance of mutations on the TIRAP protein function was
predicted by the SIFT (http://sift.jcvi.org/)32 and I-TASSER (http://zhanglab.
ccmb.med.umich.edu/I-TASSER/) tools.33 The human 30UTR sequence of
the MyD88 gene was scanned for the identiﬁcation of regulatory elements
using the Encyclopedia of DNA Elements (ENCODE; http://encodeproject.
org/ENCODE/).
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Heterozygosity at the A625C Polymorphic Site of the MyD88 Gene Is
Associated with Mycobacterium bovis Infection in Cattle
Rosanna Capparelli,a Francesco De Chiara,a Nunzia Nocerino,a Chiara Medaglia,a Rosa Di Costanzo,a Luigi Ramunno,a
Federico Capuano,b Francesco Casalinuovo,c Antonio Di Matteo,a Domenico Iannellia
Department DiSSPAPA, University of Naples, Portici, Naples, Italya; Istituto Zooprofilattico Sperimentale del Mezzogiorno, Sezione Portici, Naples, Italyb; Istituto
Zooprofilattico Sperimentale del Mezzogiorno, Sezione Catanzaro, Catanzaro, Italyc
The study demonstrates that in cattle, animals heterozygous at the MyD88 A625C polymorphic marker have a 5-fold reduced
risk for active pulmonary tuberculosis (odds ratio [OR] 0.19; P 6 1012). The reduced risk, however, does not extend to
animals with latent pulmonary tuberculosis (OR 0.83; P 0.40). Heterozygosity at the A625C single nucleotide polymor-
phism is associated with intermediate levels of tumor necrosis factor alpha, gamma interferon, and nitric oxide synthase (NOS).
Accordingly, deficiency as well as overexpression of proinflammatory cytokines or NOS favor tuberculosis, while heterozygosity
provides the animals with the optimal level of inflammation.
The causative agent of bovine tuberculosis, Mycobacterium bo-vis, has a broad host range, which includes numerous wild and
farm animal species. M. bovis is also pathogenic in humans. M.
tuberculosis, themain agent of human tuberculosis, instead is non-
pathogenic in cattle (1). This characteristic is attributed to differ-
ences in gene expression between the two bacterial species (2). In
countries where programs for the eradication of bovine tubercu-
losis are operative, the periodic testing of cattle herds for tubercu-
losis infection, meat inspection, and milk pasteurization have re-
duced to1% the cases of human tuberculosis attributable toM.
bovis and confined them primarily to people infected with HIV or
exposed to prolonged contact with animals (veterinarians or ab-
attoir workers) (3). Nevertheless, bovine tuberculosis remains rel-
evant as a zoonosis and because of the major economic losses that
it causes to the cattle industry from the slaughter of infected—and
often valuable—animals, quarantine of infected herds, and re-
strictions on animal export.
Innate and adaptive immune responses to mycobacteria rely
on Toll-like receptors (TLRs), which sense several mycobacterial
components. Sensing of the mycobacterial DNA requires TLR9,
while heat shock protein 65 (HSP65) requires TLR4 and the lipo-
mannan (LM), lipoarabinomannan (LAM), 19-kDa lipoprotein
(19LP), and soluble tuberculosis factor (STF) require TLR2 (4).
All TLRs (with the exception of TLR3) critically depend upon
myeloid differentiation factor 88 (MyD88) to link bacterial recog-
nition by TLRs with NF-B activation and cytokine production
(5). Evidence of the crucial role played byMyD88 as a signal trans-
ducer is provided byMyD88-knockout (MyD88/) mice, which
die within 4 weeks from the time of infection withM. tuberculosis
(4, 5). MyD88 / mice infected with M. tuberculosis display re-
duced expression of gamma interferon (IFN-), tumor necrosis
factor alpha (TNF-), and nitric oxide synthase (NOS). This ob-
servation has suggested that MyD88 controls the infection by reg-
ulating the production of these mediators (6).The above-de-
scribed studies and the high genetic similarity (99.95% identity at
the nucleotide level) of the M. tuberculosis andM. bovis genomes
(7) collectively provided biological plausibility to the hypothesis
of a functional role of theMyD88 gene against bovine tuberculosis
infection. The present study shows that heterozygosity at the
MyD88 A625C polymorphic site is associated with resistance
against active—but not latent—M. bovis infection in cattle.
MATERIALS AND METHODS
Diagnosis of pulmonary infection. Postmortem samples were collected
according to European Food Safety Authority (EFSA) recommendations
(8). In the case of animals displaying macroscopic pulmonary lesions, a
portion of the diseased tissue and afferent lymph node was collected. In
the case of animals without visible lesions, the mediastinal, retropharyn-
geal, and bronchial lymph nodes were collected. Individual lung homog-
enates consisted of 1 g or more of pooled specimens collected from each
animal. To distinguish between subjects with active tuberculosis pulmo-
nary infection (ATI) or latent tuberculosis pulmonary infection (LTI),
10-fold dilutions (101 to 108) of individual lung homogenates in sterile
phosphate-buffered saline were spotted (10 l/spot; 5 spots/dilution) on
agar-Middlebrook (MB) medium and incubated at 37°C for 4 to 5 weeks.
At the end of the incubation time, the numbers of CFU were counted.
Negative samples were incubated for 10 days in liquid MB medium sup-
plemented (5 g/ml) with the mycobacterial resuscitation-promoting
factor B (RpfB) (9), spotted on agar-MB medium, and incubated for 4 to
5 weeks, and the numbers of CFU were then counted. The optimal con-
centration of RpfB to use in the assay was found during preliminary ex-
periments. The growth of colonies in the absence of RpfBwas indicative of
ATI, and the growth of colonies only in the presence of RpfB was indica-
tive of LTI. Controls were negative by both tests.
Identification of mycobacterial species by PCR. One colony of M.
bovis was dispersed in 200 l of distilled H2O containing lysozyme (20
mg/ml; Sigma-Aldrich, St. Louis,MO) and incubated at 37°C for 2 h. After
incubation, DNA was isolated using a DNeasy blood and tissue kit from
Qiagen (Hilden, Germany). PCR was carried out as described previously
(10).
Cases and controls. The animals included in the study—both cases
and controls—were from three herds declared to be infected. To exclude
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sex and age as potential confounders, the animals were all lactating cows
between 40 and 90 months of age. This age interval was selected to repre-
sent subjects matched for age (as much as it was realistic) and, at the same
time, a population sample sufficiently numerous to provide adequate
power to the study. The average ages of the cases and controls were 65.4
5.2 and 69.6 3.9 months, respectively. To curb stratification, both cases
and controls were from the same herds and the same breed (Friesian); to
keep cases and controls genetically unrelated to each other, when mother
and daughter were present, one of the two was excluded.
MyD88 genotyping. The intron/exon boundaries of the bovine
MyD88 gene were established by matching the published mRNA se-
quence of the bovine MyD88 gene (GenBank accession number
NM_001014382.2) and the DNA sequence of the human MyD88 gene
(GenBank accession number NC_000003.11). Alignment was carried out
using DNAsis software (Hitachi Solutions America, San Francisco, CA).
DNA was extracted from lung specimens with a QIAamp DNA kit (Qia-
gen, Hilden, Germany). The primers were 5=-TGAAGGAGTACCCCGC
GC-3= (forward) and 5=-GATGCCTGCCATGTCATT-3= (reverse). Con-
ditions of the PCR were 7 min at 97°C and then 45 s at 94°C, 30 s at 60°C,
and 1.5 min at 72°C (35 cycles), with a final extension for 5 min at 72°C.
The 1,210-bp fragments from 20 cases and 20 controls were sequenced
using an ABI 3730 DNA analyzer (Applied Biosystems, Foster City, CA)
and aligned by use of Chromas software (Technelysium, Queensland,
Australia). The sequences were used to design primers and TaqMan
probes targeting specifically the single nucleotide polymorphism (SNP)
located 625 bp downstream of exon 1 (A625C). The forward and reverse
unlabeled primers were 5=-GGTGGCGTGGTACTTTGC-3= and 5=-TTT
CTCCTCTACGGGCTGTCT-3=, respectively. The TaqMan VIC- and
6-carboxyfluorescein-labeled probes were 5=-TAGCAAGGGAGACAT
T-3= and 5=-TAGCAAGGGCGACATT-3=, respectively, where the under-
lining and boldface indicate the polymorphic nucleotide. PCR conditions
were 30 s at 60°C, 10 min at 95°C, and then 40 cycles each lasting 15 s at
95°C and 1min at 60°C. Genotyping was carried out with the investigator
blinded to the case or control status of the animals being tested.
TaqMan gene expression assay. TNF-, IFN-, and NOS2 mRNA
levels in the lung specimens were measured using the TaqMan gene expres-
sion assay and a StepOne instrument (Applied Biosystems, Foster City, CA).
Total RNA (2 g) was reverse transcribed using a High Capacity cDNA re-
verse transcription kit (Applied Biosystems, Foster City, CA). The real-time
quantitative PCRs were carried out following the manufacturer’s protocol.
The identification numbers of the probes are Bt03259155_g1 (TNF- bo-
vine),Bt03212722_g1 (IFN-), Bt03249602_g1 (NOS2), andBt03279175_g1
(-actin). Five animals for each genotype (AA, AC, CC) and class (control,
active and latent tuberculosis) were tested in triplicate. Relative sample quan-
tification was carried out by the comparative 2		CT method (where CT
represents the threshold cycle). The endogenous control gene was -actin.
The amplification efficiency of target (TNF-, IFN-, and NOS) and refer-
ence (-actin) genes was approximately the same (slope 0.1).
Sample size calculation.The data for 50 cases with active tuberculosis
and 50 controls (odds ratio [OR], 0.3; proportion of controls with suscep-
tible genotype, 0.46) showed that a sample of 127 cases and 127 controls
would provide 96% power and a two-sided significance level of 0.01. The
study enrolled 150 animals with acute tuberculosis, 150 animals with la-
tent tuberculosis, and 300 controls.
Other methods. Fisher’s exact test and analysis of variance with the
Tukey post hoc test were performed with GraphPad Prism software, ver-
sion 5. Binary logistic regression was performed with the SPSS statistical
package, version 18.Hardy-Weinberg equilibriumand relative risk reduc-
tion were calculated as described previously (see references 11 and 12,
respectively). Conservation analysis was carried out on 11 MyD88
genomic sequences retrieved from theNucleotide BLAST database (blast-
.ncbi.nlm.nih.gov/). The alignment was performed using the T-COFFEE
multiple-sequence alignment server (tcoffee.crg.cat/) and map visualized
with CLC Main Workbench software, version 6.8.2. The bovine intron 1
sequence was scanned for identification of overrepresented motifs by us-
ing the SCOPE (Suite for Computational identification of Promoter Ele-
ments) motif finder (http://genie.dartmouth.edu/scope/). Regulatory el-
ements were searched for using the Encyclopedia of DNA Elements
(ENCODE; http://encodeproject.org/ENCODE/).
RESULTS
Diagnosis of cases and controls. Pulmonary tuberculosis infec-
tion can be active (ATI) or latent (LTI); the latter is characterized
by the presence of dormant bacteria (viable but not culturable on
usual growth media) (13). The methods commonly used to diag-
nose latent tuberculosis are the tuberculin skin test (TST) or the
IFN- release assay. However, these methods do not distinguish
between hosts still infected and those which successfully con-
trolled infection (14). In the present study, grouping together dif-
ferent phenotypes would sensibly reduce the power of the study
(15). M. tuberculosis has 5 resuscitation-promoting factor (rpf)
genes coding for as many redundant proteins (RpfA to RpfE)
which, in the form of recombinant proteins expressed in Esche-
richia coli, induce resuscitation of M. tuberculosis (16) and M.
marinum (17) in vitro and ex vivo. On the basis of these findings,
an in-house assay aimed at resuscitating dormant mycobacteria
with the RpfB protein was developed. It was possible to recover
dormantM. bovis from sevenmilk and seven lung specimens from
animals treated with the RpfB protein but not from any of the
specimens from animals untreated with RpfB when 20 of the an-
imals included in the study were tested. The results for milk and
lung specimens from the 20 animals were fully concordant. This
material was used to validate the method. The test was therefore
extended to all the animals, using lung specimens collected post-
mortem. A PCR assay discriminating betweenM. tuberculosis,M.
bovis, orM. avium established that all cases (with ATI or LTI) were
infected with M. bovis. In conclusion, the cases with ATI were
subjects positive by the PCR assay and the bacteriological test in
the absence of RpfB; the cases with LTI were positive by the PCR
assay and the bacteriological test in the presence of RpfB; controls
were subjects exposed toM. bovis infection (since they were from
the same herds that also supplied the cases) but free from infection
(negative by the PCR assay and the bacteriological tests in the
presence or absence of RpfB) (Fig. 1).
Study design. The criticism more often leveled at association
studies is that they lack reproducibility (18, 19). To curb this draw-
back, a two-stage study was designed. The preliminary (hypothe-
sis-generating) stage involved 50 control animals, whichwere sep-
arately confronted with 50 cases with ATI or 50 cases with LTI.
This preliminary study displayed a significant association of the
MyD88 polymorphic site A625C with ATI (P
 0.01; Table 1) but
not with LTI (P
 0.84; Table 1). The A625C polymorphic site is
located in intron 1 of the MyD88 gene (Fig. 2). The study also
yielded the following valuable data: first, that the association is
potentially robust (since it was detected using a small number of
subjects) and, second, that case stratification according to the
form (active or latent) of the infection would definitively provide
more power to the study. Other than A625C, the SNPs shown in
the reference sequence (Fig. 2) were not present in the sample
population studied.
To explore the functional role of A625C further, 11 Myd88
genomic sequences were analyzed for conservation across species
(Fig. 3). The low level of conservation suggested that the A625C
position is not under stringent selection. Scanning of the bovine
intron 1 sequence with SCOPE highlighted 4 overrepresented nu-
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cleotide motifs, which included the polymorphic site (Table 2),
evoking a possible regulatory role of the site. However, ENCODE
did not find regulatory elements within intron 1 in the bovine
MyD88, except for a CpG track. The analysis, repeated on intron 1
of the humanMyD88, tracked the transcription factor binding site
V$BACH1_01 and the chromatin immunoprecipitation (ChIP)
fragment for RNA polymerase II. Interestingly, both these tracks
overlap the bovine A625C site. Collectively, the data invited fur-
ther investigation of the potential influence of A625C onM. bovis
infection.
MyD88 heterozygosity and resistance to ATI. The study was
repeated on a larger and independent sample consisting of 300
controls, 150 cases with ATI, and 150 cases with LTI. A separate
experiment (with animals not included in the case-control study)
showed that crosses between subjects homozygous for the A or C
factor (AA CC) yielded only heterozygous (AC) offspring. The
experiment proved that A and C are transmitted as codominant
alleles (data not shown). Cases with ATI were not inHardy-Wein-
berg equilibrium (2
 4.4; Table 1). When the test was repeated
on the cases with LTI, both cases and controls were in equilibrium
(2 for controls 
 0.9; 2 for cases 
 0.3; Table 1). The results
suggested an association of the MyD88 marker with ATI but not
with LTI. First, the more cogent Fisher’s exact test showed that
heterozygosity (the AC status) is strongly associated with resis-
tance to ATI (OR
 0.19, P
 6.0 1012; Table 1); second, the
association remained strong when the homozygous classes were
pooled (OR
 0.22; P
 1.8 1010; Table 1); third, the MyD88
marker did not influence the predisposition to LTI (OR 
 0.81
and 0.83; P
 0.36 and 0.40; Table 1). The binary logistic regres-
sion test supported these conclusions (Table 3). Given the fre-
quency of the AC heterozygotes among controls (135/300
 0.45;
Table 1) and the level of protection afforded (OR
 0.19; Table 1),
this genotype prevented 36% [0.45  (1  0.19) 
 0.36] of the
potential cases of ATI in the population examined (12).
MyD88 heterozygosity and inflammation. TNF-, IFN-,
andNOS are known to profoundly influence tuberculosis (6). It is
also known that high as well as low levels of inflammation nega-
tively impact this disease (4, 5, 20). Thus, if the MyD88 heterozy-
gotes displayed intermediate cytokine levels compared to those of
homozygotes, the association between A625C heterozygosity and
resistance toM. bovis infection would gain strong biological plau-
sibility. To test this hypothesis, the levels of TNF-, IFN-, and
NOS of subjects with different genotypes (AA, AC, CC) and status
(controls or animals with ATI or LTI) (6 classes; 5 animals/class)
were measured. The expression levels of the subjects with ATI or
LTI were then compared with those of control subjects having the
same genotype. Heterozygous carriers expressed levels of TNF-,
IFN-, and NOS significantly lower than those expressed by the
AA homozygotes. Instead, carriers expressed levels only slightly
higher than those expressed by the CC homozygotes; in this case,
the difference did not reach statistical significance (Fig. 4). One
possible explanation for this heterogeneity is that the technique
used does not discriminate below a threshold level. Taken to-
gether, the data support the conclusion that an optimal inflamma-
tory response is associated with the intermediate A625C pheno-
type.
TABLE 1 Heterozygosity at the A625C SNP influences active pulmonary tuberculosis infection
Study
stage TB typea Status
No. of cows with the following
genotype:
2b
AC vs AA AC vs (AA CC)
AA AC CC Total OR (CIc) P OR (CI) P
1 Active Cases 36 10 4 50 5.2 0.30 (0.12–0.74) 0.001 0.29 (0.12–0.71) 0.01
Controls 25 23 2 50 1.4
Latent Cases 28 21 1 50 1.7 0.81 (0.36–1.81) 0.68 0.85 (0.38–1.87) 0.84
Controls 25 23 2 50 1.4
2 Active Cases 123 23 4 150 4.4 0.19 (0.11–0.32) 6 1012 0.22 (0.12–0.37) 1.8 1010
Controls 140 135 25 300 0.9
Latent Cases 75 60 15 150 0.3 0.83 (0.53–1.28) 0.40 0.81 (0.53–1.23) 0.36
Controls 140 135 25 300 0.9
a TB type, type ofM. bovis pulmonary tuberculosis infection.
b 20.05 (1 degree of freedom)
 3.8.
c CI, 95% confidence interval.
FIG 1 Diagnostic criteria used to classify subjects into controls or subjects
with ATI or LTI. Controls, subjects with and without RpfB negative by culture
and PCR tests; ATI, subjects without RpfB positive by culture and PCR tests;
LTI, subjects with RpfB positive by culture and PCR tests.
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DISCUSSION
The present study demonstrates that in cattle, animals heterozy-
gous at the MyD88 A625C polymorphic marker benefit from a
5-fold reduced risk for ATI (OR
 0.19; P
 6 1012; Table 1).
The reduced risk, however, does not extend to the animals with
LTI (OR
 0.83; P
 0.40; Table 1). Heterozygosity at the A625C
SNP is associated with intermediate levels of IFN-, TNF-, and
NOS (Fig. 4). What is the biological advantage of an intermediate
level of production of these mediators in the case of active tuber-
culosis? The short answer is that heterozygosity provides the op-
timal level of inflammation. The deficiency of IFN-, TNF-, or
NOS favors tuberculosis (4, 5). At the same time, some symptoms
of the disease are known to be caused by the immune response of
the host rather than by the mycobacterium (20). Episodes of dis-
ease reactivation and inflammatory syndrome related to preexist-
ing M. tuberculosis (21) or M. avium (22) infection have been
observed in HIV-coinfected patients after antiretroviral therapy.
The study also displays differences in cytokine expression among
animals of the same genotype with acute or latent tuberculosis.
This difference is particularly evident in the case of the AA animals
(Fig. 4).Whether the differences are caused by themycobacterium
or the host immune response, these results, though preliminary,
point to increased levels of proinflammatory cytokine expression
as potential markers of disease reactivation. The A625C polymor-
phism—located in intron 1 of theMyd88 gene—adds evidence to
the notion that noncoding regions can influence gene expression.
It is not surprising that this also occurs in the case of inflamma-
tion, which needs to be under fine and complex regulation.
In cattle, exposure to environmental mycobacteria, which occurs
in themajorityof the subjects, interfereswith thediagnosisofM.bovis
infection by the tuberculin skin test (TST) or the IFN- assay (23).
Variability in the reagents, incubation time, and diagnostic cutoff
levels also influence the specificity and sensitivity of these assays (24).
The postmortem culture test—still the “gold standard” method
(25)—was therefore preferred for the diagnosis of infection.Also, the
limits of theTSTand IFN- assays and—on theother side—thehigh
prevalence of M. bovis infection among the enrolled animals (150
subjects with acute infection and asmanywith latent infection out of
approximately 650 randomly tested animals) persuaded the authors
that the number of false-positive and false-negative results would be
betterminimizedbyassuming that all controlswereexposed subjects,
rather than relying on the TST or the IFN- assay for exposure diag-
nosis. The authors do not claim that the method adopted here is
superior to currentmethods in general; rather, they trust that it yields
a better-defined disease spectrum andmore reproducible results un-
der a case-control design.
Tuberculosis is influenced by several genes interacting among
themselves (26) and with the environment (15). The presence of
the mycobacterium is necessary but not sufficient to acquire the
disease, as shown by the control subjects, which, exposed to the
pathogen, did not acquire the disease (Table 1); see also the work
of Diamond (27). Environmental factors (climate, herd size, ani-
mal purchases, cattle movements) are known to promote bovine
tuberculosis (2). Even strong genetic effects onM. tuberculosis can
be missed when environmental effects are not taken into account
(15). We claim that the unusually small OR and P values (OR 

FIG 2 Position of the A625C SNP on the MyD88 gene. The map is oriented 5= to 3=. Source: www.ncbi.nlm.nih.gov/gene/444881.
FIG 3 Alignment and conservation analysis of 11mammalianMyD88 sequences within a region surrounding the polymorphic site under study (marked with a black
line).
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0.19; P 
 6.0  1012) reported in the present study reflect how
the problems confronting the genetic analysis of this complex dis-
ease were solved. Cases were made homogeneous (active and la-
tent tuberculosis cases were analyzed separately), and the environ-
mental confounders were either excluded (sex and breed) or
randomized (age). More importantly, control subjects were from
the same source population as the cases. Controls were therefore
subjects that remained infection free (negative by the bacteriolog-
ical and PCR tests), though they had the same opportunity as the
cases to become infected. Population stratification often has been
claimed to be responsible for false-positive results in association
studies, yet rarely has it been demonstrated to be the culprit (28,
29). Human studies have shown that stratificationmight originate
when different ethnicities are mixed (30). In the present study,
only one breed was studied. Furthermore, replication of the asso-
ciation across 2 independent population samples argues against
the result being a product of population stratification.
Genetic association studies are characterized by a high rate of
false-positive results (29). This condition is often due to the selec-
tion of a candidate gene without a functional relation to the dis-
ease (29, 31). In the present study, MyD88 was selected on the
basis of a large body of experimental data showing that—at least in
mice—this gene is critical for signaling downstream the presence
of mycobacterial components and inducing the production of the
innate responsemediators (IFN-, TNF-, andNOS) againstmy-
cobacteria (4, 5). Further, the two-stage study design allowed the
reproducibility of the association to be directly proved. Replica-
tion of the results at the time that they are first described is gaining
consensus as an approach for reducing the number of false-posi-
tive results (28, 32). The two-stage designwas also of value to define
the precise phenotype (active versus latent M. bovis infection) to
study (Table 1). In conclusion, the high biological relevance of the
gene to study, the accurate choice of diagnostic criteria, and random-
ization of environmental confounderswere all carefully kept inmind
during thepresent journey in thepuzzlingfieldof association studies.
However, since theassociation isbeingdescribed for thefirst time, the
results of this study are presented as preliminary.
Lastly, the test used here to differentiate between acute and
latent disease could potentially be extended to the periodic testing
of cattle for tuberculosis. The count of dormant mycobacteria
awakened by RpfB in milk samples would be an easy way to know
the prevalence of latent tuberculosis in the population, a param-
eter greatly influencing the control of the pathogen.
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TABLE 2 Nucleotide motifs overrepresented in the bovine intron 1
sequencea
Sequenceb
Searched consensus
sequence
Counts within
the Bos taurus
genome
GGGTAGCAAGGGAGACA GGGNVNVDDDSSHSACA 5
GGGAGACATTGGAGACA GGGNVNVDDDSSHSACA 5
AGGGA AGGGA 7
AGGGAGACAT AGGGRBVCAT 3
a Motifs were identified using the SCOPEmotif finder (http://genie.dartmouth.edu/scope/).
All strands were plus strands, and 100% coverage was achieved for all sequences.
b The polymorphic nucleotide is underlined.
TABLE 3 Heterozygosity at the A625C SNP and resistance to active
pulmonary tuberculosis shown by binary logistic regression
Reference
genotype TBa
Binary logistic regression analysis result
Wald P eb H-L Pc
AA Active 40 1.8 1010 0.19 1
Latent 0.78 0.37 0.83 1
CC Active 0.01 0.91 1 1
Latent 0.68 0.40 0.74 1
a TB,M. bovis pulmonary tuberculosis infection.
b Odds ratios estimated by the binary analyses.
c The nonsignificance of the Hosmer-Lemeshow (H-L) P value indicates that the model
predicted by the logistic regression fits the observed data.
FIG 4 Proinflammatory cytokine mRNA levels measured by the TaqMan gene
expression assay. Specimens were from controls or animals with active (ATI) or
latent (LTI)M.bovis infection.Animalswere grouped according to genotype (AA,
AC, orCC) and class (controls, subjectswithATI or LTI). Each group consisted of
5 subjects. (A to C) Levels of TNF-, IFN-, andNOSmRNA expression, respec-
tively. Relative sample quantification was carried out by the comparative 2		CT
method. The endogenous control was the -actin gene.
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http://www.biomedcentral.com/1471-2172/13/61RESEARCH ARTICLE Open AccessNew perspectives for natural antimicrobial
peptides: application as antinflammatory drugs in
a murine model
Rosanna Capparelli1*, Francesco De Chiara1, Nunzia Nocerino1, Rosa Chiara Montella1, Marco Iannaccone1,
Andrea Fulgione1, Alessandra Romanelli2, Concetta Avitabile2, Giuseppe Blaiotta3 and Federico Capuano4Abstract
Background: Antimicrobial peptides (AMPs) are an ancient group of defense molecules. AMPs are widely
distributed in nature (being present in mammals, birds, amphibians, insects, plants, and microorganisms). They
display bactericidal as well as immunomodulatory properties. The aim of this study was to investigate the
antimicrobial and anti-inflammatory activities of a combination of two AMPs (temporin B and the royal jellein I)
against Staphylococcus epidermidis.
Results: The temporin B (TB-KK) and the royal jelleins I, II, III chemically modified at the C terminal (RJI-C, RJII-C,
RJIII-C), were tested for their activity against 10 different Staphylococcus epidermidis strains, alone and in
combination. Of the three royal jelleins, RJI-C showed the highest activity. Moreover, the combination of RJI-C and
TB-KK (MIX) displayed synergistic activity. In vitro, the MIX displayed low hemolytic activity, no NO2
- production and
the ability to curb the synthesis of the pro-inflammatory cytokines TNF-α and IFN-γ to the same extent as
acetylsalicylic acid. In vivo, the MIX sterilized mice infected with Staphylococcus epidermidis in eleven days and
inhibited the expression of genes encoding the prostaglandin-endoperoxide synthase 2 (COX-2) and CD64, two
important parameters of inflammation.
Conclusion: The study shows that the MIX – a combination of two naturally occurring peptides - displays both
antimicrobial and anti-inflammatory activities.Background
Coagulase-negative staphylococci (CoNS) are highly abun-
dant on the human skin, already a few hours after birth.
The CoNS Staphylococcus epidermidis is an ubiquitous
and permanent colonizer of human skin and the first
cause of nosocomial infections [1]. Most infections with
high morbidity and mortality are caused by methicillin-
resistant strains of Staphylococcus epidermidis (MRSE)
[2,3]. In addition, many MRSE strains form a capsule
which favors biofilm development, where the pathogen
can persist protected from antibiotics and invisible to
the immune system [4,5].
New, unconventional antimicrobials are therefore ur-
gently needed [6,7]. In this context, antimicrobial peptides* Correspondence: capparel@unina.it
1Faculty of Biotechnology, University of Naples “Federico II”, Naples 80134,
Italy
Full list of author information is available at the end of the article
© 2012 Capparelli et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or(AMPs), in their natural form or after chemical modifica-
tion, display interesting features as candidates to become
new antimicrobials. They have a broad spectrum of activ-
ity against Gram-positive and Gram-negative bacteria,
can be easily synthesized in laboratory and have limited
toxicity for eukaryotic cells [8,9]. As innate immune
components, AMPs lack specificity and immune mem-
ory, with the consequence that the pathogens rarely de-
velop resistance to them [10]. Importantly, AMPs rapidly
intercept and kill pathogens [11]. AMPs differ each other
by size, sequence and secondary structure (α-helix or β-
sheet) [12]. Most of them are hydrophobic and amphi-
pathic [13]. AMPs can exert their activity by disrupting
the membrane [14] or passing through the bacterial
membrane [15]. Molecules belonging to the former class
of AMPs permeabilize the membrane phospholipids bi-
layer and kill the bacterial cell; those belonging to the
latter class pass through the bacterial membrane andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as traditional antibiotics. AMPs, in addition to the anti-
microbial activity, display also immune-modulatory
properties (such as chemiotaxis, which contributes to
bacterial elimination) and interact with natural and adap-
tive immunity [16,17]. Thus, in view of the above proper-
ties, AMPs represent one of the most promising future
strategies for combating infections and microbial drug
resistance. The present study describes two chemically
modified AMPs - an analogue of the temporin B
(TB-KK) secreted by the granular glands of the European
red frog (Rana temporaria) [18] and an analogue of the
royal jellein I (RJI-C) secreted by the mandible and hypo-
pharyngeal glands of honeybees (Apis mellifera) [9,19].
These two peptides behave differently towards the bac-
terial membrane. RJI-C folds into beta sheets and aggre-
gates onto the membrane; TB-KK folds into an alpha
helix and does not aggregate onto the membrane [8,9].
Recent data demonstrate that hydrophobic peptides,
when mixed with peptides possessing a net posi-
tive charge, give origin to a mixture with potential anti-
bacterial activity [20,21]; second, that the combination of
antimicrobial peptides derived from different organisms
are highly active against Gram positive bacteria [9]. In
agreement with these results, here we show that a mix-
ture of TB-KK and RJI-C – two AMPs derived from differ-
ent sources - displays strong antimicrobial activity against
Gram-positive bacteria - modulates pro-inflammatory cy-
tokines and nitric oxide production, in vitro and in vivo.
The two peptides, following chemical modification, po-
tentially can be made available in large quantities and in
a homogeneous and highly pure form.
Results
Characterization of Staphylococcus epidermidis strains
To establish the clonal origin of the Staphylococcus epi-
dermidis strains used in the study, the strains (10) were
characterized phenotypically - with respect to their anti-
biotic resistance pattern and molecularly with respect to
their Restriction Endonucleases Analysis (Pulse Field Gel
Electrophoresis - REA-PFGE) pattern. All strains re-
sulted resistant to aztreonam (30 μg; ATM30), bacitracin
(10 μg; B2), cloxacillin (1 μg; CX1) and metronidazole
(80 μg; M80) and sensitive to imipenem (10 μg; IPM10).
The remaining 25 antibiotics displayed a strain specific
pattern (Table 1). Also, with one exception (the strain
SE), the strains displayed all different macro-restriction
patterns, when analyzed by Sma I REA-PAGE (Figure 1).
Thus, the strains used in this study belong to different
clonal lineages.
In vitro antimicrobial activity of TB-KK and RJI-C
To evaluate the antimicrobial activity of RJI-C, RJII-C,
RJIII-C and TB-KK (Table 2) these AMPs were testedin vitro [8,9], individually and in combination, against
10 Staphylococcus epidermidis strains. Among the three
royal jelleins, RJI-C showed the highest activity (MIC:
30 μg/ml) (Table 3). Tested in various combination (RJI-C
at 20 μg/ml and RJII-C at 5–20 μg/ml ; RJI-C at 20 μg/ml
and RJIII-C at 5–20 μg/ml; RJII-C at 20 μg/ml and RJIII-C
at 5–20 μg/ml), the royal jelleins did not display synergis-
tic effects. Only RJI-C was thus tested for synergism with
TB-KK. The combination of the two antimicrobials –
RJI-C at 9 μg/ml and TB-KK at 6 μg/ml (MIX) – displayed
a fractional inhibitory concentration index ≤ 0.5, which
is evidence of synergism [20] (Table 3). The strains
of Staphylococcus epidermidis were all sensitive to the
MIX, but not its components (Table 4). This conclu-
sion is supported by the larger inhibition ring of
the MIX, compared to that of the individual components
(Figure 2A).
Interestingly, the antibacterial activity of the MIX
against probiotics bacteria (Lactobacillus plantarum,
Lactobacillus Paracasei, Bifidobacterium animalis) was
five-fold lower than that of gentamicin (Table 5).
In vitro hemolytic and cytotoxic activities of the MIX
To test the cytotoxic activity of the MIX, we used the
hemolytic and the LC50 assays. The MIX lysed less than
12% of the murine erythrocytes (data not shown) and
the LC50 value was 143,8 mg/ml versus 58.5 μg/ml of
TB-KK and 64.6 μg/ml of RJI-C (Additional file 1: Table
S1). The MIX was not toxic towards the macrophage
J774 cells, which remained vital at 72 hours (Figure 2B).
In vitro the MIX does not induce synthesis of NO-2
The MIX (RJI-C at 9 μg/ml and TB-KK at 6 μg/ml) did
not induce NO2
- synthesis in J774 cells. Rather, when
these cells were stimulated with LPS (10 μg/ml/well for
3 hours) and then treated with the RJ-IC, TB-KK and
MIX reduced NO2
- synthesis (Table 6), one of the para-
meters to determine the cellular toxicity.
In vitro anti-inflammatory activity of the MIX
To investigate whether the MIX, in addition to the anti-
microbial activity, also displays anti-inflammatory activ-
ity, J774 cells (106 cells/well) were stimulated with either
LPS or LTA (0.1, 1 or 10 μg/ml) for 3 hours. The results
show that LPS stimulates inflammation in the J774 cells
better than LTA (Figure 3A). Later, J774 cells were trea-
ted with gentamicin (5 μg/ml), acetylsalicylic acid (ASA,
5 μg /ml) or MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml)
for 3 hours. In the absence of the agent causing inflam-
mation (LPS), the MIX, gentamicin and ASA do not in-
duce inflammation (Figure 3B). In J774 cells (106 cells/
well) stimulated with LPS for 3 hours, the MIX curbs
the synthesis of the pro-inflammatory cytokines TNF-α
Table 1 Results of antibiotic susceptibility tests of ten Staphylococcus epidermidis strains
Antibiotics tested
Strain FD10 P120 AMX25 AM10 ATM30 B2 CB100 CD30 FOX30 CAZ30 A30 CX1 K15 FF50 GM10 IPM10 MY2 M80 MZ75 NET30 FM300 NB30 T30 P10 PIP100 RF30 SP100 RL100 TE30 VA30
SE R R R R R R R R I S I R R S R S R R R R R R I R R R R R R R
3/28 R I S S R R R S S I I R R R R S R R S I S S S R S S S R I I
2/2 S R R R R R R R R I S R R R I S R R R I S S S R R I R R I I
5/6 I R I R R R I R I S I R R R I S I R R I S S S R R S I R I I
5/8 S R I R R R I R I I R R R S R S R R R I S S R R R S S R S S
12/14 S R R R R R I R S S R R R R R S S R R I S S R R R R I R R I
9/1 S R R R R R I R S I S R S S I S S R R S S S S R R S I R S I
10/28 S I R R R R R R S I R R R S R S S R R I S S R R R S I R I I
12/26 S R R R R R R R S I S R S S R S S R R I S S S R R S I R S I
5/25 S R R R R R R R S I S R R I I S R R R I S S S R R S I R S S
R= strain resistant to the antibiotic.
S= strain sensitive to the antibiotic.
I= intermediate strains sensitive to the antibiotic.
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Table 2 Peptide sequences and mass analysis of the royal
jelleins (RJ) and temporin (TB) used in the study
Peptide Sequence Calc. mass (DA) Meas. mass (DA)
RJI-C PFKIDIHLGGY-NH2 1230.46 1231.02
RJII-C TPFKISIHLGGY-NH2 1331.56 1331.90
RJIII-C EPFKISIHLGGY-NH2 1359.57 1360.10
TB YLLPIVGNLLKSLL-NH2 1391.80 1391.20
TB-KK. KKYLLPI VGNLLKSLL-NH2 2295.40 2294.30
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http://www.biomedcentral.com/1471-2172/13/61and IFN-γ more efficiently than gentamicin and at the
same extent of the ASA (Figure 3C).
These experiments demonstrate that the MIX exerts
anti-inflammatory as well as antimicrobial activities, while
the single components of the MIX have no anti-
inflammatory activity (Additional file 2: Figure S1). Since
COX-2 is a well-established parameter of inflammation
[22] , the J774 cells were stimulated with LPS (10 μg/ml)
and 1 hour later treated with the MIX, RJII-C (non-active
peptide), acetylsalicylic acid (ASA), gentamicin or vehicle
(PBS) for 3 hours. The level of the COX-2 protein was
then detected by western blot. The MIX-treated cells, dis-
played a COX-2 protein level comparable to that of the
cells treated with ASA or gentamicin, and much lower
than that of the cells treated with RJII-C or the vehicle
(Figure 3D). The above results demonstrate that the MIX
curbs inflammation to the same extent as ASA [23].
In vivo anti-inflammatory activity of the MIX in mice
stimulated with LPS
To investigate further the property of the MIX to
curb inflammation in vivo, LPS (250 μg, ~10 mg/Kg)Figure 1 Sma I REA (Restriction Endonucleases Analysis)-PFGE pattern
(Invitrogen); 2) strain 5/25; 3) strain9/1; 4) strain 2/2; 5) strain 10/28; 6
strain SE (untypable); 11) strain 3/28; 12) Lambda DNA - Hind III Dige
(Bio-Rad); 14) PFGE marker, 0.225–2.2 Mb S. cerevisiae chromosomalwas administrated to four groups of mice (3 mice/
group). After 3 hours, the groups were treated re-
spectively with the MIX (RJI-C 9 μg/mouse + TB-KK
6 μg/mouse), gentamicin (5 μg in 100 μl/mouse) or
ASA (5 μg in 100 μl/mouse). The last group received
100 μl of saline buffer as control. After 3 hours, the
mice that received the MIX showed a reduced level
of both the pro-inflammatory cytokines TNF-α and
IFN-γ, when compared to gentamicin-treated group,
but an higher expression level of IFN- γ, when com-
pared to the ASA group (Figure 3E). In conclusion,s of Staphylococcus epidermidis strains: 1) 1Kb plus DNA Ladder
) strain 12/14; 7) strain 5/8; 8) strain 12/26; 9) strain 5/6; 10)
sted (Invitrogen); 13) DNA Size Standards - Lambda Ladder
DNA (Bio-Rad).
Table 3 The FIC index against Staphylococcus
epidermidis strains: ≤ 0.5, synergy ; >0.5, no interaction
Antimicrobial peptides MIC100 Fic index
RJI-C 30 μg/ml (24 μM)
RJII-C 200 μg/ml (150 μM)
RJIII-C 300 μg/ml (220 μM)
TB-KK 7 μg/ml (3 μM)
Gentamicin 5 μg/ml (10 μM)
RJI-C + TB-KK 9 μg/ml + 6 μg/ml
(7.3 μM + 2.6 μM)
0.5
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http://www.biomedcentral.com/1471-2172/13/61the MIX performs better than gentamicin, but worse
than ASA.In vivo antimicrobial efficacy of the MIX given
intravenously at 12 hours post infection
To evaluate the efficacy of the MIX to contrast microbial in-
fection, four groups of mice (15 mice/group) were infected
with lethal dose (108 CFU/mouse) of Staphylococcus epi-
dermidis (SE). This strain was chosen since it is resistant
to the majority of the antibiotics tested (Table 1).
One group did not receive any treatment (control
group); a second group received sterile PBS (100 μl/
mouse) (placebo group – data not shown); the third
group received the MIX (RJI-C 9 μg/mouse + TB-KK
6 μg/mouse); the fourth group received gentamicin
(5 μg/mouse). PBS, MIX and gentamicin were adminis-
tered intravenously at 3 hours post infection. In both,
placebo and control groups, the bacterial load of kidneys
and spleens increased progressively, while it decreased
in the groups treated with gentamicin or the MIX
(Additional file 3: Figure S2). Upon treatment of the
mice with the MIX, the acute phase proteins, which
represent important markers of inflammation [24],
were evaluated (Additional file 4: Table S2). The SAA
(Serum amyloid A), haptoglobin and fibrinogen were
within normal ranges in the mice treated with the MIX orTable 4 Antimicrobial activity of the MIX and its components
Strains % inhibition of bacterial growth
RJI-C 9 μg/ml (7.3 μM)
% inhibition of bacterial gr
TB-KK 6 μg/ml (2.6 μM
3/28 17 ± 2 19 ± 2
2/2 18 ± 1 23 ± 0.5
5/6 4 ± 3 10 ± 1
5/8 12 ± 2 21 ± 2
12/14 11 ± 0.5 20 ± 3
9/1 18 ± 0 26 ± 2
10/28 0 4 ± 1
12/26 19 ± 2 14 ± 2
5/25 15 ± 1 21 ± 1with gentamicin, while significantly high in the control
mice (infected but not treated) (Additional file 4: Table S2).In vivo anti-inflammatory efficacy of the MIX given
intravenously at 12 hours post infection
The four groups of mice described before have been
used also to evaluate the anti-inflammatory activity of
the MIX. For this purpose, the expression levels of the
TNF-α , IFN-γ, IL-10 cytokine genes were measured at 3,
6 and 9 hours after treatment in the kidney samples
(Figure 4A-C, respectively). In the group treated with the
MIX, the TNF-α and IFN-γ were under expressed (at 6,
9 hours from treatment), as compared to the group treated
with gentamicin (Figure 4A-C). This result suggests that
the MIX controls inflammation better than gentamicin.
Also CD64 and COX-2 markers of inflammation
in vivo were evaluated. Blood samples were collected 3,
6, or 9 hours after the treatments. CD64 was measured
by flow cytometry (Figure 5A). Six and nine hours after
the treatment with gentamicin or the MIX, the mice
displayed a decreased expression of the CD64 marker
(Figure 5A). The level of COX-2, was evaluated by RT-
PCR on the mRNA extracted from kidney samples. In
control mice displayed a significantly higher expression
level of COX-2, compared to the mice treated with MIX
or gentamicin. In the control mice COX-2 peaked 3 hours
after the treatment. In the mice treated with gentamicin
or the MIX, COX-2 expression level returned to the nor-
mal level nine hours after the treatment (Figure 5B).
To verify whether the MIX affected granulocytic infil-
tration in the kidneys of infected mice, hematoxylin-
eosin staining was performed. As expected, kidneys of
control mice displayed granulocytic infiltration within
the lumen of the cortical convoluted tubules and hence
lymphocytic infiltration, vessel activation and glomerular
hyperplasia (Figure 6 panel 1, 5). Instead, kidneys of
MIX-treated mice showed a dramatic reduction in the
number of granulocytic cells localized in the corticalagainst different strains of Staphylococcus epidermidis
owth
)
% inhibition of bacterial growth RJI-C 9 μg/ml + TB-KK
6 μg/ml (RJI-C 7.3 μM + TB-KK 2.6 μM) (MIX)
91 ± 1
96 ± 2
100 ± 0
95 ± 2
92 ± 1
96 ± 2
100 ± 0
100 ± 0
90 ± 2
Figure 2 (A) Antimicrobial activity of the single peptides (RJI-C 9 μg/ml; RJII-C 15 μg/ml; TB-KK 6 μg/ml) and of MIX (RJI-C at 9 μg/ml
and TB-KK at 6 μg/ml) are shown as inhibition zone assay. A larger zone of inhibition is evident around the MIX compared to the single
components. (B) J774 cell line treated with the single peptides (RJI-C 9 μg/ml; RJII-C 15 μg/ml; TB-KK 6 μg/ml) or the MIX (RJI-C at 9 μg/ml and
TB-KK at 6 μg/ml) maintain the same growth rate compare to the untreated control.
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http://www.biomedcentral.com/1471-2172/13/61convoluted tubules, less glomerular hyperplasia, and no
lymphocyte infiltration (Figure 6 panel 2–4).In vivo antimicrobial efficacy of the MIX for the period
of 12 days
To test the antimicrobial activity of the MIX in vivo for
a longer period, mice were infected with a sub-lethal
dose (107 CFU/mouse) of Staphylococcus epidermidis
and then treated with the MIX. Four groups of mice (24
mice/group) were infected with the bacterial strain (SE).
One group of mice did not receive any treatment (con-
trol group); a second group received sterile PBS (100 μl/
mouse) (placebo group); the third group received the
MIX (RJI-C: 9 μg/mouse + TB-KK: 6 μg/mouse); the
fourth group received gentamicin (5 μg/mouse). PBS,
MIX and gentamicin were administered intravenously in
three boosts 3, 6 and 9 days post infection. In the pla-
cebo and the control groups, the bacterial load of kid-
neys and spleens (the target organs of the pathogen)
increased progressively, while the load was significantly
lower in the groups treated with gentamicin or the MIX.
Eleven days after the infection, the mice treated with
gentamicin were still infected, while those treated with
the MIX were already sterile (Figure 7A-B).Table 5 Antimicrobial activity of the MIX or gentamicin
on probiotic bacteria
Strains MIX RJI-C 9 μg/ml
+TB-KK 6 μg/ml
(RJI-C 7.3 μM +TB-KK
2.6 μM)
Gentamicin
5 μg/ml
(10 μM)
Bifidobacterium
animalis
29% ± 3 96% ± 4
Lactobacillum
plantarum
23% ± 2 97% ± 4
Lactobacillum
paracasei
25% ± 2 96% ± 3Four days after the infection, in addition to spleen and
kidneys (106 CFU/gr and 107 CFU/gr respectively), the
bacterium was also detected (at a threshold level:
102 CFU/g) in the liver (data not shown). Thus, the MIX
is slightly more effective than gentamicin (Figure 7A-B).
In all four groups, bacteria were no longer detected
in the blood circulation within 2 h from infection
(Additional file 5: Figure S3).
In vivo anti-inflammatory efficacy of the MIX for the
period of 12 days
To evaluate the anti-inflammatory activity of the MIX,
the expression levels of the TNF-α, IFN-γ, IL-10 cyto-
kines genes were measured in the kidneys. The experi-
ment was carried out on the same four groups of mice
described in the previous paragraph. For this purpose,
the expression levels of the cytokines were measured 24
and 48 hours after each treatment with MIX (or 4, 5, 7,
8,10 and 11 days post infection). In the group treated
with the MIX, compared to the group treated with genta-
micin, the TNF-α and IFN-γ levels were under expressed
(at 7 days) while the IL-10 levels were over expressed (at
10 days) (Figure 7C). This result suggests that the
MIX controls inflammation better than gentamicin.
Discussion
Recently we demonstrated that new antimicrobials are
more effective than traditional antibiotics against Staph-
ylococcus epidermidis [25,26]. The present study extends
these results, providing evidence that the MIX – a mix-
ture of a royal jellein modified at the C-terminal (RJI-C)
and an analogue of temporin B (TB-KK) – is a valid al-
ternative to the use of gentamicin against skin infections
caused by Staphylococcus epidermidis.
In vivo, endogenous antimicrobial peptides (such as
human defensins and cathelecidins) are known to be
pleiotropic: they act as antimicrobials [27]; neutralize
Table 6 NO2
- production of J774 cells: Mouse macrophages untreated, treated with RJI-C, TB-KK or the MIX, stimulated
with LPS, stimulated with LPS and treated with RJI-C, TB-KK or the MIX
Treatment Time of incubation (h)
24 48 72
No treatment 0.25 ± 0.04 0.69 ± 0.02 0.92 ± 0.2
RJI-C (15 μg/ml) (12 μM) 0.42 ± 0.03 0.75 ± 0.01 1.02 ± 0.3
TB-KK (15 μg/ml) (6.5 μM) 0.82 ± 0.05 1.25 ± 0.2 1.34 ± 0.2
MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml) (RJI-C 7.3 μM + TB-KK 2.6 μM) 0.72 ± 0.3 0.85 ± 0.3 1.06 ± 0.2
LPS (10 μg/ml) 2.93 ± 0.2 10.96 ± 0.4 12.16 ± 0.5
LPS + RJI-C (15 μg/ml) (12 μM) 2.85 ± 0.3 8.42 ± 0.1 10.21 ± 0.2
LPS + TB-KK (15 μg/ml) (6.5 μM) 3.12 ± 0.6 9.75 ± 0.1 11.45 ± 0.2
LPS + MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml) (RJI-C 7.3 μM + TB-KK 2.6 μM) 2.63 ± 0.4 7.25 ± 0.3 8.26 ± 0.1
Data are expressed as micromoles of NO2- for 106 input cells, and are means ± standard deviation of three different experiments each performed in triplicate.
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would induce an excess of inflammation and tissue dam-
age [28,29]; attract inflammatory cells to the wound site
and promote wound healing.
The two exogenous components of the MIX also behave
in a pleiotropic fashion: they control the bacterial load
(Figure 7A-B and Additional file 3: Figure S2), inhibit the
synthesis of pro-inflammatory cytokines (Figures 4 and
7C) and control the expression of COX-2 (Figures 3D
and 5B), the acute phase proteins (Additional file 4:
Table S2) and the expression of the CD64 receptor
(Figure 5A). At the histological level, the MIX reduces
kidney lymphocyte infiltration (Figure 6).
Mice infected with a sub-lethal dose of Staphylococcus
epidermidis and three days later treated with the MIX
(RJI-C: 9 μg/mouse + TB-KK: 6 μg/mouse), within 11 days
from treatment, displayed sterile kidneys and spleen –
the organs targeted by the bacterial strain used in this
study (Figure 7A-B). Samples collected at 15 min inter-
vals from infection showed that bacteria leave the blood
circulation within 2 h (Additional file 5: Figure S3). These
results are clinically relevant since they suggest that the
MIX can potentially be used in humans, where infection
is generally caused by a small initial inoculum and treat-
ment is therefore initiated several days after infection
(Figure 7A-B).
The MIX is not toxic for eukaryotic cells, in vitro and
in vivo (Figure 2B); its components act synergistically
(Figure 2A) and becomes moderately hemolytic (12%).
In addition, the MIX reduces the synthesis of NO2
- in
cells infected with Staphylococcus epidermidis (Table 6).
These additional properties make the MIX a candidate
for a new generation drug.
In vitro and in vivo experiments demonstrate that the
MIX down regulates the level of the pro-inflammatory
cytokines TNF−α and IFN-γ while enhancing the ex-
pression of the anti-inflammatory cytokine IL-10. This
effect is comparable to that of gentamicin, a well-knownantimicrobial drug. These results confirm that the MIX,
in addition to an antibacterial activity, also exerts –
in vivo and in vitro - an anti-inflammatory activity.
The intestinal flora represents a defense barrier
against pathogens [30]. We therefore also investigated
whether the MIX spared probiotic bacterial species
in vitro. While gentamicin killed the totality of the pro-
biotics tested (Lactobacillus plantarum, Lactobacillus
Paracasei, Bifidus animalis), the MIX killed a minority
of each bacterial species (29%-23%-25%, respectively)
(Table 5).
The influence of the MIX on the major cell signal-
ing pathways was also studied. CD64 and COX-2
warn about the cell exposure to inflammatory stimuli
[31,32]. The MIX reduced the expression level of
COX-2 (Figures 3D and 5B) and CD64 (Figure 5A),
proofing that the MIX exerts also anti-inflammatory
activity. The CD64 levels are high in the mice
infected. In the mice infected and then treated with
MIX at both 3, 6 and 9 hours from treatment, levels
of CD64 are reduced (Figure 5A). This last result pro-
vides evidence that the MIX has effects on mechan-
isms of both innate and adaptive immunity.
Conclusions
This study provided evidence which suggests an analogy
between endogenous AMP and the MIX, consisting of
exogenous and chemically modified AMPs. Both display
a two-fold role, rapidly recognizing the presence of a
pathogen and preventing an excess of inflammation.
Methods
Bacteria
List and origin of Staphylococcus epidermidis used in
this study is reported in Additional file 6: Table S3. All
strains were isolated from patients hospitalized at the
Medical School of the University of Naples Federico II.
All strains were molecular identified by means of kat
Figure 3 (A) TNF-α, IFN-γ, IL-10 mRNA expression levels in J774
cells stimulated with LPS or LTA (0,1,1 or 10 μg/ml) for 3 hours.
(B) J774 cells treated with gentamicin (5 μg/ml) or MIX (RJI-C
9 μg/ml + TB-KK 6 μg/ml) or ASA (5 μg/ml) for 3 hours. (C) J774
cells stimulated with LPS (10 μg/ml) for 3 hours and treated with
gentamicin (5 μg/ml) or MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml) or ASA
(5 μg/ml) for further 3 hours. (D) Western blot analysis of COX-2 in
J774 cell line. Lane 1–3: J774 cells + LPS(10 μg/ml); Lane 4–6: J774
cells + LPS (10 μg/ml) + inactive peptide (RJII-C 15 μg/ml);
Lane 7–9: J774 cells + LPS (10 μg/ml) + ASA (5 μg/ml); Lane 10–12:
J774 cells + LPS (10 μg/ml) + MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml;
Lane 13–14: J774 cells + LPS (10 μg/ml) + gentamicin (5 μg/ml).
(E) TNF-α, IFN-γ, IL-10 mRNA expression levels in kidney of mice
(3mice/group) stimulated with LPS (250 μg, ~10 mg/Kg) for 3 hours;
stimulated with LPS (250 μg, ~10 mg/Kg) for 3 hours and treated
with gentamicin (5 μg/mouse) or MIX (RJI-C 9 μg/mouse + TB-KK
6 μg/mouse) or ASA (5 μg/mouse) for 3 hours. Values were
normalized with GAPDH and compared to untreated control.
*P <0.05, **p < 0.01; ***p < 0.001, Student’s t test gentamicin vs MIX
and gentamicin vs ASA.
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[33].
The study does not investigate clinical aspects of the
disease, nor it uses human specimen. The study there-
fore does not require the Ethic Committee approval.Antibiotic susceptibility of Staphylococcus epidermidis strains
The antibiotic-susceptibility profile of strains was tested
using the disk diffusion method on Mueller-Hinton agar,
according to the NCCLS guidelines (2002) [34]. The an-
tibiotics used and their concentrations were as follows:
amoxicillin (25 μg; AMX25), ampicillin (10 μg; AM10),
aztreonam (30 μg; ATM30), bacitracin (10 μg; B2), car-
benicillin (100 μg; CB100), ceftazidime (30 μg; CAZ30),
cefoxidin (30 μg; FOX30), cephaloridine (30 μg; CD30),
cloxacillin (1 μg; CX1), erythromycin (15 μg; E15), fosfo-
mycin (50 μg; FF50), fusidic acid (10 μg; FD10), gentamicin
(10 μg; GM10), imipenem (10 μg; IPM10), lincomycin
(2 μg; MY2), metronidazole (80 μg; M80), mezlocillin
(75 μg; MZ75), netilmycin (30 μg; NET30), nitrofurantoin
(300 μg; FM300), novobiocin (30 μg, NB30), oxytetracyc-
line (30 μg, T30), penicillin-G (10 μg; P10), piperacillin
(100 μg, PIP100), rifampicin (30 μg; RF30), chlorotetracy-
cline (30 μg; A30), spiramycin (100 μg; SP100), sulfa-
methoxazole (100 μg; SP100), tetracycline (30 μg; TE30),
and vancomycin (30 μg; VA30). All antibiotics were pro-
vided by BioMérieux SA, (Marcy l’Etoile, France).
Pulsed-field electrophoresis of Staphylococcus epidermidis
strains
The procedure adopted was that described [35]. Briefly,
inserts of intact DNA were digested in 200 μl of appro-
priate buffer supplemented with 40 U of Sma I (Promega,
Milan). Pulsed field gel electrophoresis (PFGE) of the re-
striction digests was performed by using the CHEF sys-
tem (Bio-Rad Laboratories, Hercules, CA, USA) with 1%
(wt/vol) agarose gels and 0.5 x TBE as running buffer, at
10°C. Restriction fragments were resolved in a single run, at
constant voltage of 6 V cm2 and an orientation angle of
120° between electric fields, by a single phase procedure
for 24 h with a pulse ramping between 1 and 50s.
Figure 4 (A-C) TNF-α, IFN-γ, IL-10 mRNA expression levels in
infected mice with Staphylococcus epidermidis (108 CFU/mouse)
or infected with Staphylococcus epidermidis (108 CFU/mouse)
and treated with the MIX (RJI-C at 9 μg/mouse and TB-KK at
6 μg/mouse) or gentamicin (5 μg/mouse) at 3(A), 6 (B) and 9 (C)
hours after treatment. Values were normalized with GAPDH and
compared to untreated control. *P <0.05, **p < 0.01; ***p < 0.001,
Student’s t test gentamicin vs MIX.
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Antibacterial activity of the peptides used in this work was
evaluated as described previously [8]. A potential syner-
gism (FIC) between TB-KK and RJI-C (MIX) was evalu-
ated by adding combinations of two peptides in a serial
two-fold dilutions (RJI-C 5–100 μg, 40 μl/well; TB-KK 5–
100 μg, 40 μl/well;) to wells containing 105 CFU/well in
60 μl [8]. The fractional inhibitory concentration (FIC)
index for combinations of two peptides was calculated
according to the equation: FIC index = FICA + FICB = A/
MICA + B/MICB , where A and B are the MICs of drug
A and drug B in the combination, MICA and MICB are
the MICs of drug A and drug B alone, and FICA and FICB
are the FICs of drug A and drug B. The FIC indices wereinterpreted as follows: ≤0.5, synergy; 0.51–4.0, no inter-
action; > 4.0, antagonism [23].
The growth inhibition percentages of Staphylococcus
epidermidis and probiotic strains were assessed under
the same conditions.
Inhibition zone assay and test of the haemolytic activity
of the antimicrobials
The MIX (RJI-C at 9 μg/ml and TB-KK at 6 μg/ml) was
tested for its haemolytic activity using mouse red blood
cells and for inhibition zone assay test [8]. The MIX was
tested for its haemolytic activity using mouse red blood
cells. The blood was collected from the tail of the animals
and centrifuged (4x102 g for 3 min). The erythrocytes were
washed with saline, suspended at 3x106 erythrocytes/ml,
mixed with the peptide combination (RJI-C 9 μg and TB-
KK 6 μg in 100 μl saline) and incubated for 1 h at 37°C.
The haemolytic activity was measured according to the
formula OD peptide - OD negative control/OD positive control -
OD negative control X 100 where the negative control (0%
haemolysis) was represented by erythrocytes suspended
in saline and the positive control (100% haemolysis) was
represented by the erythrocytes lysed with 1% triton
X100 [36].
The LC50 values relative to the two peptides and the
MIX were calculated as described [37].
Cell culture
J774 murine macrophages from the American Tissue
Culture Collection (ATCC, Rockville, MD,USA) were
cultured in Dulbecco's modified Eagle's medium (DMEM,
Cambrex Bio Science, Verviers, Belgium). Culture media
contained 10% fetal bovine serum (FBS, Sigma, Milan,
Italy), 100 IU/ml penicillin, 100 μg/ml streptomycin (all
from Gibco, Paisley, Scotland). Cells were seeded on 96-
well plates (Falcon, Milan) for the MTT Assay, and on
24-well plates (Falcon, Milan) for NO2
− measurements,
fluorescence microscopy analysis, and RT-PCR assays.
Cell monolayers were grown to adherence before the
experiments were started.
Mice
Experiments were carried out on female BALB/c mice
(aged 8 to 10 weeks) at the animal facility of the Univer-
sity of Naples. Bacteria (107 or 108 CFU/mouse) were
inoculated by intravenous routes (i.v.). LPS (250 μg,
~10 mg/Kg) (Sigma-Aldrich Milan), or an equivalent
volume of sterile 0,9% saline vehicle (250 μl) was admi-
nistered intraperitoneally. Blood samples were drawn
from the tail vein using 0.5 ml syringes. Spleen and kid-
ney were collected at several time points (4,5,7,8,10,
11and 12 days) after the mice infection with a sub-lethal
dose of Staphylococcus epidermidis (107 CFU/mouse).
However the same organs were also collected at 3, 6, 9
Figure 5 (A) Using flow cytometry, CD64 levels were measured at 3, 6 and 9 hours after treatment in blood samples from mice
infected with Staphylococcus epidermidis (108 CFU/mouse), from mice infected with Staphylococcus.epidermidis (108 CFU/mouse) and
treated either with MIX (RJI-C at 9 μg/mouse and TB-KK at 6 μg/mouse) or with gentamicin (5 μg/mouse). (B) mRNA expression level of
COX-2, measured in kidneys of Staphylococcus.epidermidis (108 CFU/mouse ) infected mice and in kidneys of Staphylococcus epidermidis
(108 CFU/mouse) infected mice and treated with MIX (RJI-C at 9 μg/mouse and TB-KK at 6 μg/mouse) or gentamicin (5 μg/mouse) . *p <0.05,
**p < 0.01; ***p < 0.001, Student’s t test gentamicin vs MIX.
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ylococcus epidermidis (108 CFU/mouse). Spleens and
kidneys were dissected and weighed. One g of each sam-
ple was homogenized in 1 ml saline and serially diluted
in saline.
Colony forming units (CFU) were evaluated by the
plate count assay. Animal experiments were approved by
the Animal Care Committee of the University of Naples.
Measurement of cell viability
Analysis of cell viability was performed using the CellTi-
ter 96W AQueous One Solution Cell Proliferation Assay
system (MTS assay) (Promega, Madison,WI, USA). J774
cells were seeded at 2500 cells per well in a 96-well plate
and incubated at 37°C, in a humidified atmosphere with5% CO2. TB-KK 15 μg/ml, RJI-C 15 μg/ml, MIX (TB-KK
6 μg/ml + RJI-C 9 μg/ml) or RJII-C (Control 15 μg/ml)
were added to the medium immediately after cell ad-
hesion. At each time point 20 μl of CellTiter 96W
AQueous One Solution reagent was added to each
well, according to the manufacturer's instructions.
Absorbance was recorded at 490 nm after 2 h using
an EnVision 2102 multilabel reader (PerkinElmer,
Waltham, USA).
Nitrite formation in J774 cells stimulated with LPS and
treated with RJI-C, TB-KK, and the MIX
Nitrite accumulation (NO2
−, μmol/106 cells) in the cell
culture medium was determined by the Griess reac-
tion [38].
Figure 6 Haematoxylin eosin staining. Kidney sections from
Staphylococcus epidermidis (108 CFU/mouse) infected mice after 3 or
9 hours (panel 1and 5); kidney sections from Staphylococcus
epidermidis (108 CFU/mouse) infected mice after 3 hours and treated
with MIX (RJI-C at 9 μg/mouse and TB-KK at 6 μg/mouse) for 3,
6 and 9 hours (panel 2–4).
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Cell lysates for Western blotting were prepared by wash-
ing cells twice with ice-cold phosphate-buffered saline
followed by cell lysis in 500 μl of Fastprep lysis buffer
(1X protease inhibitor cocktail tablet (Roche EDTA free)
resuspended in 1X PBS) on ice and lysed 20s at 6.5 in-
tensity, 2X intervalling with 5–10 minutes on ice. Cell
lysates were centrifuged for 10 min at 7800 g at 4°C, and
the supernatants were collected and stored at −80°C until
analysis. Lysate protein concentrations were measured
using the Bio-Rad protein assay method, as described in
the manufacturer’s instructions. Cell lysate volumes cor-
responding to 20 μg of total protein were diluted 1:1 inLaemmli buffer (Bio-Rad) and boiled for 5 min prior to
electrophoresis on a 10% acrylamide gel. The resolved
proteins were electroblotted on PVDF membrane (Bio-
Rad) by the Bio-Rad semidry transfer method, according
to the manufacturer’s instructions. Membranes were
stained with PonceauRed to verify uniform protein trans-
fer, and then blocked with blocking buffer (1X TBS, 0.1%
Tween-20, 5% w/v non-fat dry milk) for 1 h at RT.
Blocked membranes were incubated overnight at 4°C
with COX-2 mouse monoclonal antibody (diluted 1/
2000), β-actin mouse monoclonal antibody (diluted 1/
10,000). Blots were washed three times in TBS-Tween
before incubation with the appropriate horseradish
peroxidase-conjugated secondary antibody (sheep anti-
mouse IgG diluted 1/5000) for 1 h at room temperature.
After three washes with TBS-Tween, the signal was
developed using standard procedure. Gel image was
acquired in Fujifilm LAS-3000 Chemiluminescence sys-
tem (Fujifilm Life science).
Real time PCR of pro-inflammatory
Total RNA was isolated from the tissue and the cell line
after treatment by using Trizol reagent (Invitrogen,
Milan, Italy). RNA was suspended in RNase-DNAse free
distilled water, assessed for concentration (by measuring
the absorbance at 260 nm) and purity (by ascertaining
that the A260/A280 ratio was .1.9). RNA (1 μg) was then
treated with 1U RNAse-free DNAse (Promega, Madison,
WI). DNA contamination of RNA samples was excluded
by PCR with primers specific for the gapdh gene. Re-
verse transcription was carried out with ImProm-II re-
verse transcriptase (Promega, Madison, WI) and oligo
(dT). Real-time PCR was performed on 50 ng cDNA,
using 1x master mix SYBRGreen (Applied Biosystem,
Milan) in a StepOne Applied Biosystem instrument
(Applied Biosystem, Milan). Reactions were performed
in 20 μl in triplicate. The primer list is reported in
Additional file 7: Table S4.
ELISA test of pro-inflammatory cytokines
In addition, the ELISA test was used to measure the
anti-inflammatory activity of the MIX and its compo-
nents : RJI-C 9 μg/mL e TB-KK 6 μg/mL.
Briefly, J774 cells (106 cells/well) were stimulated with
LPS (10 μg/ml; 1 hour), treated with RJI-C 9 μg/ml or
TB-KK 6 μg/ml or MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml)
in presence or absence of LPS (10 μg/ml). The super-
natants from these cells (100 μl/well) were transferred
into the wells of a plate previously coated with mouse
anti-human TNF-α (BD Pharmingen; 50 μl diluted 2 x
10-3/well) or mouse anti-human IFN-γ (Biosciences,
50 μl diluted 2 x 10-3/well) along with a second dose of
anti IFN- γ or TNF- α, HRP-labelled rabbit anti mouse
IgG diluted 10-3 (100 μl/well) and TMB peroxidase
Figure 7 (A-B) Bacterial load in spleen and kidneys of animals (24/groups) infected with Staphylococcus epidermidis (107 CFU/mouse;
rumble line); infected with Staphylococcus epidermidis(107 CFU/mouse) and treated with the MIX (RJI-C at 9 μg/mouse and TB-KK at
6 μg/mouse; square line) or gentamicin (5 μg/mouse; triangle line) *P <0.05, **p < 0.01; ***p < 0.001, Student’s t test gentamicin vs
MIX. (C) TNF-α, IFN-γ, IL-10 mRNA expression levels were quantified, at the indicated time points, in mice infected with Staphylococcus epidermidis
(107 CFU/mouse) or infected with Staphylococcus epidermidis (107 CFU/mouse) and treated with three different doses (I,II,III) of the MIX (RJI-C at
9 μg in 100 μl/mouse and TB-KK at 6 μg in 100 μl/mouse) or gentamicin (5 μg in 100 μl/mouse). Values were normalized with GAPDH and
compared to untreated control. *P <0.05, **p < 0.01; ***p < 0.001, Student’s t test gentamicin vs MIX.
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tical density of each well was read at 405 nm using a
microplate reader (Bio-Rad, Japan). Triplicate positive
and negative controls were included in each plate [39].
Cytofluorimetric analysis
CD64 expression in total White Blood Cells was ana-
lyzed using a Flow cytometry EPICS Elite (BeckmanCoulter, Fullerton, CA). Daily instrument quality control
including fluorescence standardization, linearity assess-
ment, and spectral compensation were performed to en-
sure identical operation from day to day. At least 10.000
events for each sample was analyzed and the data were
saved for later analysis on EXPO32 software (Beckman
Coulter). Data analysis was performed by using elec-
tronic gating on the basis of FSC and SSC excluded
Capparelli et al. BMC Immunology 2012, 13:61 Page 13 of 14
http://www.biomedcentral.com/1471-2172/13/61cellular debris and nonviable cells. PE-coniugated anti-
mouse CD64 expression was measured using a log10
scale. Briefly, 50 ul of whole blood was incubated for
10 minutes at room temperature with saturating
amounts of phycoeritrine- conjugated anti-CD64 mur-
ine monoclonal antibody (Becton Dickinson) followed
by red blood cell lysis with an ammonium chloride–
based red cell lysis solution (Beckman Coulter, Fuller-
ton, CA). Samples were then washed once and resus-
pended with phosphate-buffered saline at pH 7.4, to a
volume of 1 mL.
Other methods
The kidney was fixed in 10% buffered formalin, sec-
tioned (10 μm) and stained with hematoxylin-eosin
according to standard protocols. Bacterial counts and
cytokine levels were analyzed using Student’s t test.
Additional files
Additional file 1: Table S1. Lethal concentration (LC50) of Temporin
B –KK, Royal jelleins-IC, MIX through their hemolytic activity on mouse
erythrocytes.
Additional file 2: Figure S1. Anti-inflammatory activity. The levels of
IFN- γ and TNF- α were determined by a sandwich ELISA test in J774
cells untreated; J774 cells infected with S. epidermidis for 1 h; J774 cells
stimulated with RJI-C (9 μg/ml) for1 h; J774 cells stimulated with TB-KK.
(6 μg/ml) for1 h; J774 cells stimulated with MIX (RJI-C 9 μg/ml + TB-KK
6 μg/ml) for1 h; J774 cells infected with S. epidermidis for 1 h and
stimulated with MIX for 1 h. Results from two representative experiments
are presented as mean value ± S.D. *P <0.05, **p < 0.01; ***p < 0.001,
Student’s t test S. epidermidis vs S. epidermidis + MIX.
Additional file 3: Figure S2 (A-B). Bacterial load in spleen and kidneys
of S. epidermidis infected mice (rumble line) and subsequently treated
with the MIX (square line) or gentamicin (triangle line). Data are
representative of 15 animals/group. Student’s
t test gentamicin vs MIX not significant.
Additional file 4: Table S2. Acute phase proteins. Acute phase proteins
from blood samples of mice infected with Staphylococcus epidermidis and
treated with MIX or with Gentamicin.
Additional file 5: Figure S3. Time course (30, 60, 90 and 120 minutes)
of bacterial load in blood of S. epidermidis infected mice.
Additional file 6: Table S3: Origin of S. epidermidis strains.
Additional file 7: Table S4: Sequences of the primers.
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